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Introduction
In 1996, the World Health Organization (WHO) pub-
lished the first edition of the Medical Eligibility Criteria for 
Contraceptive Use (MEC), which gave evidence-based guidance 
on the safety of contraceptive method use for women and 
men worldwide who had specific characteristics and medical 
conditions. Since that time, WHO has regularly updated its 
guidance on the basis of new evidence, and the WHO MEC 
is now in its fourth edition (1).
CDC, through close collaboration with WHO, has con-
tributed substantially during the last 15 years to creation of 
WHO’s global family planning guidance, which includes four 
documents: the medical eligibility criteria for contraceptive 
use, the selected practice recommendations for contraceptive 
use, a decision-making tool for clients and providers, and a 
global family planning handbook. This WHO guidance has 
been based on the best available scientific evidence, and CDC 
has served as the lead for establishing that evidence base and 
presenting the evidence to WHO for use during its expert 
working group meetings to create and update the guidance.
WHO has always intended for its global guidance to be used 
by local or regional policy makers, managers of family planning 
programs, and the scientific community as a reference when 
they develop family planning guidance at the country or pro-
gram level. The United Kingdom is one example of a country 
that has adapted the WHO MEC for its own use (2).
CDC undertook a formal process to adapt the WHO MEC 
at this time because the fourth edition of the WHO guidance is 
unlikely to undergo major revisions in the near future. Although 
the WHO guidance is already available in the United States 
through inclusion in textbooks, use by professional organizations, 
and incorporation into training programs, the adaptation of the 
guidance ensures its appropriateness for use in the United States 
and allows for further dissemination and implementation among 
U.S. health-care providers. Most of the U.S. guidance does not 
differ from the WHO guidance and covers approximately 60 char-
acteristics or medical conditions. However, several changes have 
been made, including adaptations of selected WHO recommenda-
tions, addition of recommendations for new medical conditions, 
and removal of recommendations for contraceptive methods not 
currently available in the United States (Appendix A).
This document contains recommendations for health-care 
providers for the safe use of contraceptive methods by women 
and men with various characteristics and medical conditions. It is 
intended to assist health-care providers when they counsel women, 
men, and couples about contraceptive method choice. These 
recommendations are meant to be a source of clinical guidance; 
health-care providers should always consider the individual 
clinical circumstances of each person seeking family planning 
services.
U S. Medical Eligibility Criteria for Contraceptive Use, 2010
 Adapted from the World Health Organization Medical Eligibility Criteria 
for Contraceptive Use, 4th edition
Prepared by
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Summary
CDC created U.S. Medical Eligibility Criteria for Contraceptive Use, 2010, from guidance developed by the World Health 
Organization (WHO) and finalized the recommendations after consultation with a group of health professionals who met in 
Atlanta, Georgia, during February 2009. This guidance comprises recommendations for the use of specific contraceptive methods by 
women and men who have certain characteristics or medical conditions. The majority of the U.S. guidance does not differ from the 
WHO guidance and covers >60 characteristics or medical conditions. However, some WHO recommendations were modified for 
use in the United States, including recommendations about contraceptive use for women with venous thromboembolism, valvular 
heart disease, ovarian cancer, and uterine fibroids and for postpartum and breastfeeding women. Recommendations were added 
to the U.S. guidance for women with rheumatoid arthritis, history of bariatric surgery, peripartum cardiomyopathy, endometrial 
hyperplasia, inflammatory bowel disease, and solid organ transplantation. The recommendations in this document are intended 
to assist health-care providers when they counsel women, men, and couples about contraceptive method choice. Although these 
recommendations are meant to serve as a source of clinical guidance, health-care providers should always consider the individual 
clinical circumstances of each person seeking family planning services.
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Methods
The process for adapting the WHO MEC for the United 
States comprised four major steps: 1) determination of the 
scope of and process for the adaptation, including a small 
meeting; 2) preparation and peer review of systematic reviews 
of the evidence to be used for the adaptation; 3) organization 
of a larger meeting to examine the evidence and provide input 
on the recommendations; and 4) finalization of the recom-
mendations by CDC.
In June 2008, CDC held a 2-day meeting of eight key 
partners and U.S. family planning experts to determine the 
scope of and process for a U.S. adaptation of the WHO MEC. 
Participants were family planning providers, who also had 
expertise in conducting research on contraceptive safety and 
translating research evidence into guidance. WHO guidance is 
used widely around the world, including in the United States, 
and contains approximately 1,800 separate recommendations. 
In most cases, the evidence base would be the same for the 
U.S. and the WHO recommendation, and—because of the 
extensive collaboration between WHO and CDC in creating 
the international guidance—the process for determining the 
recommendations also would be the same. Therefore, CDC 
determined that the global guidance also should be the U.S. 
guidance, except when a compelling reason existed for adap-
tation, and that CDC would accept the majority of WHO 
guidance for use in the United States.
During the June 2008 meeting, CDC identified specific 
WHO recommendations for which a compelling reason 
existed to consider modification for the United States because 
of the availability of new scientific evidence or the context in 
which family planning services are provided in the United 
States. CDC also identified areas in which WHO guidance 
was inconsistent with current U.S. practice by contacting 
numerous professional and service organizations and individual 
providers. In addition, CDC assessed the need for adding rec-
ommendations for medical conditions not currently included 
in the WHO MEC. Through this process, a list was developed 
of existing WHO recommendations to consider adapting and 
new medical conditions to consider adding to the guidance.
A systematic review of the scientific evidence was conducted 
for each of the WHO recommendations considered for adap-
tation and for each of the medical conditions considered for 
addition to the guidance. The purpose of these systematic 
reviews was to identify direct evidence about the safety of 
contraceptive method use by women (or men) with selected 
conditions (e.g., risk for disease progression or other adverse 
health effects in women with rheumatoid arthritis who use 
combined oral contraceptives). Information about indirect 
evidence (e.g., evidence from healthy women or animal studies) 
or theoretical considerations was obtained when direct evidence 
was not available. CDC conducted systematic reviews follow-
ing standard guidelines (3,4), included thorough searches of 
PubMed and other databases of the scientific literature, and 
used the U.S. Preventive Services Task Force system to grade 
the strength and quality of the evidence (5). Each systematic 
review was peer-reviewed by two or three experts before being 
used in the adaptation process. These systematic reviews have 
been submitted for publication in peer-reviewed journals.
For most recommendations in this document, a limited 
number of studies address the use of a specific contraceptive 
method by women with a specific condition. Therefore, within 
the WHO guidance, as well as with this U.S. adaptation of 
the guidance, most of the decisions about medical eligibility 
criteria were often necessarily based on 1) extrapolations from 
studies that primarily included healthy women, 2) theoretical 
considerations about risks and benefits, and 3) expert opinion. 
Evidence was particularly limited for newer contraceptive 
methods. The total body of evidence for each recommendation 
included evidence based on direct studies or observations of 
the contraceptive method used by women (or men) with the 
condition and may have included 1) evidence derived from 
effects of the contraceptive method used by women (or men) 
without the condition and 2) indirect evidence or theoretical 
concerns based on studies of suitable animal models, human 
laboratory studies, or analogous clinical situations.
In February 2009, CDC held a meeting of 31 experts who 
were invited to provide their individual perspective on the 
scientific evidence presented and the discussions on poten-
tial recommendations that followed. This group included 
obstetricians/gynecologists, pediatricians, family physicians, 
nurse-midwives, nurse practitioners, epidemiologists, and 
others with expertise in contraceptive safety and provision. 
For each topic discussed, the evidence from the systematic 
review was presented; for most of the topics, an expert in the 
BOX 1. Categories of medical eligibility criteria for 
contraceptive use
1 = A condition for which there is no restriction for 
the use of the contraceptive method.
2 = A condition for which the advantages of using 
the method generally outweigh the theoretical 
or proven risks.
3 = A condition for which the theoretical or proven 
risks usually outweigh the advantages of using 
the method.
4 = A condition that represents an unacceptable 
health risk if the contraceptive method is used.
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specific medical condition (e.g., rheumatoid arthritis) also gave 
a brief presentation on the condition and specific issues about 
contraceptive safety. CDC gathered input from the experts 
during the meeting and finalized the recommendations in 
this document. CDC plans to develop a research agenda to 
address topics identified during the meeting that need further 
investigation.
How to Use this Document
These recommendations are intended to help health-care pro-
viders determine the safe use of contraceptive methods among 
women and men with various characteristics and medical con-
ditions. Providers also can use the synthesis of information in 
these recommendations when consulting with women, men, 
and couples about their selection of contraceptive methods. 
The tables in this document include recommendations for the 
use of contraceptive methods by women and men with par-
ticular characteristics or medical conditions. Each condition 
was defined as representing either an individual’s characteris-
tics (e.g., age, history of pregnancy) or a known preexisting 
medical/pathologic condition (e.g., diabetes and hypertension). 
The recommendations refer to contraceptive methods being 
used for contraceptive purposes; the recommendations do 
not consider the use of contraceptive methods for treatment 
of medical conditions because the eligibility criteria in these 
cases may differ. The conditions affecting eligibility for the 
use of each contraceptive method were classified under one of 
four categories (Box 1).
Using the Categories in Practice
Health-care providers can use these categories when assessing 
the safety of contraceptive method use for women and men 
with specific medical conditions or characteristics. Category 
1 comprises conditions for which no restrictions exist for 
use of the contraceptive method. Classification of a method/
condition as Category 2 indicates the method generally can 
be used, but careful follow-up may be required. For a method/
condition classified as Category 3, use of that method usually 
is not recommended unless other more appropriate methods 
are not available or acceptable. The severity of the condition 
and the availability, practicality, and acceptability of alternative 
methods should be taken into account, and careful follow-up 
will be required. Hence, provision of a method to a woman 
with a condition classified as Category 3 requires careful 
clinical judgement and access to clinical services. Category 4 
comprises conditions that represent an unacceptable health 
risk if the method is used. For example, a smoker aged <35 
years generally can use combined oral contraceptives (COCs) 
(Category 2). However, for a woman aged ≥35 years who 
smokes <15 cigarettes per day, the use of COCs usually is 
not recommended unless other methods are not available or 
acceptable to her (Category 3). A woman aged ≥35 years who 
smokes ≥15 cigarettes per day should not use COCs because 
of unacceptable health risks, primarily the risk for myocardial 
infarction and stroke (Category 4). The programmatic implica-
tions of these categories may depend on the circumstances of 
particular professional or service organizations (e.g., in some 
settings, a Category 3 may mean that special consultation is 
warranted).
The recommendations address medical eligibility criteria for 
the initiation and continued use of all methods evaluated. The 
issue of continuation criteria is clinically relevant whenever a 
woman develops the condition while she is using the method. 
When the categories differ for initiation and continuation, 
these differences are noted in the columns Initiation and 
Continuation. Where Initiation and Continuation are not 
denoted, the category is the same for initiation and continu-
ation of use.
On the basis of this classification system, the eligibility crite-
ria for initiating and continuing use of a specific contraceptive 
method are presented in tables (Appendices A–M). In these 
tables, the first column indicates the condition. Several condi-
tions were divided into subconditions to differentiate between 
varying types or severity of the condition. The second column 
classifies the condition for initiation and/or continuation into 
Category 1, 2, 3, or 4. For some conditions, the numeric clas-
sification does not adequately capture the recommendation; 
in this case, the third column clarifies the numeric category. 
These clarifications were determined during the discussions of 
the scientific evidence and the numeric classification and are 
considered a necessary element of the recommendation. The 
third column also summarizes the evidence for the recom-
mendation, where evidence exists. The recommendations for 
which no evidence is cited are based on expert opinion from 
either the WHO or U.S. expert working group meetings and 
may be based on evidence from sources other than systematic 
reviews and presented at those meetings. For selected recom-
mendations, additional comments appear in the third column 
and generally come from the WHO or the U.S. expert working 
group participants.
Recommendations for Use of 
Contraceptive Methods
The classifications for whether women with certain medical 
conditions or characteristics can use specific contraceptive 
methods are provided for combined hormonal contracep-
tive methods, including low-dose (containing ≤35 μg ethi-
nyl estradiol) combined oral contraceptive pills, combined 
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hormonal patch, and combined vaginal ring (Appendix B); 
progestin-only contraceptive methods, including progestin-
only pills, depot medroxyprogesterone acetate injections, and 
etonogestrel implants (Appendix C); emergency contraceptive 
pills (Appendix D); intrauterine contraception, including the 
copper intrauterine device (IUD) and the levonorgestrel IUD 
(Appendix E); use of copper IUDs for emergency contracep-
tion (Appendix F); barrier contraceptive methods, including 
male and female condoms, spermicides, diaphragm with 
spermicide, and cervical cap (Appendix G); fertility awareness-
based methods (Appendix H); lactational amenorrhea method 
(Appendix I); coitus interruptus (Appendix J); and female 
and male sterilization (Appendix K). Tables at the end of the 
document summarize the classifications for the hormonal and 
intrauterine methods (Appendix L) and the evidence about 
potential drug interactions between hormonal contraceptives 
and antiretroviral therapies (Appendix M).
Contraceptive Method Choice
Many elements need to be considered by women, men, or 
couples at any given point in their lifetimes when choosing 
the most appropriate contraceptive method. These elements 
include safety, effectiveness, availability (including accessibil-
ity and affordability), and acceptability. The guidance in this 
document focuses primarily on the safety of a given contra-
ceptive method for a person with a particular characteristic or 
medical condition. Therefore, the classification of Category 1 
means that the method can be used in that circumstance with 
no restrictions with regard to safety but does not necessarily 
imply that the method is the best choice for that person; other 
factors, such as effectiveness, availability, and acceptability, may 
play a key role in determining the most appropriate choice. 
Voluntary informed choice of contraceptive methods is an 
essential guiding principle, and contraceptive counseling, 
where applicable, may be an important contributor to the 
successful use of contraceptive methods.
In choosing a method of contraception, the risk for sexually 
transmitted infections (STIs), including human immunodefi-
ciency virus (HIV), also must be considered. Although hormonal 
contraceptives and IUDs are highly effective at preventing 
pregnancy, they do not protect against STIs. Consistent and 
correct use of the male latex condom reduces the risk for STIs 
(6). When a male condom cannot be used properly for infection 
prevention, a female condom should be considered (7). Women 
who use contraceptive methods other than condoms should be 
counseled about the use of condoms and the risk for STIs (7). 
Additional information about prevention and treatment of STIs 
is available from CDC’s Sexually Transmitted Diseases Treatment 
Guidelines (http://www.cdc.gov/std/treatment) (7).
Contraceptive Method Effectiveness
Contraceptive method effectiveness is critically important 
in minimizing the risk for unintended pregnancy, particularly 
among women for whom an unintended pregnancy would 
pose additional health risks. The effectiveness of contraceptive 
methods depends both on the inherent effectiveness of the 
method itself and on how consistently and correctly it is used 
(Table 1). Methods that depend on consistent and correct use 
have a wide range of effectiveness.
Unintended Pregnancy and Increased 
Health Risk
For women with conditions that may make unintended 
pregnancy an unacceptable health risk, long-acting, highly 
effective contraceptive methods may be the best choice (Table 
1). Women with these conditions should be advised that sole 
use of barrier methods for contraception and behavior-based 
methods of contraception may not be the most appropriate 
choice because of their relatively higher typical-use rates of 
failure (Table 1). Conditions included in the U.S. MEC for 
which unintended pregnancy presents an unacceptable health 
risk are identified throughout the document (Box 2).
Keeping Guidance Up to Date
As with any evidence-based guidance document, a key chal-
lenge is keeping the recommendations up to date as new scien-
tific evidence becomes available. CDC will continue to work 
with WHO to identify and assess all new relevant evidence 
and to determine whether changes to the recommendations 
are warranted (4). In most cases, the U.S. MEC will follow any 
updates in the WHO guidance, which typically occur every 
3–4 years (or sooner if warranted by new data). However, 
CDC will review any WHO updates for their application in 
the United States. CDC also will identify and assess any new 
literature for the recommendations and medical conditions that 
are not included in the WHO guidance. CDC will completely 
review the U.S. MEC every 3–4 years as well. Updates to the 
guidance will appear on the CDC U.S. MEC website: http://
www.cdc.gov/reproductivehealth/UnintendedPregnancy/
USMEC.htm.
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TABLE 1. Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of 
perfect use of contraception and the percentage continuing use at the end of the first year — United States
Method
Women experiencing an unintended pregnancy 
within the first year of use
Women continuing use at 1 year§Typical use* Perfect use†
No method¶ 85% 85%
Spermicides** 29% 18% 42%
Withdrawal 27% 4% 43%
Fertility awareness–based methods 25% 51%
Standard Days method†† 5%
TwoDay method™†† 4%
Ovulation method†† 3%
Sponge
Parous women 32% 20% 46%
Nulliparous women 16% 9% 57%
Diaphragm§§ 16% 6% 57%
Condom¶¶
Female (Reality®) 21% 5% 49%
Male 15% 2% 53%
Combined pill and progestin-only pill 8% 0.3% 68%
Evra patch® 8% 0.3% 68%
NuvaRing® 8% 0.3% 68%
Depo-Provera® 3% 0.3% 56%
Intrauterine device
ParaGard® (copper T) 0.8% 0.6% 78%
Mirena® (LNG-IUS) 0.2% 0.2% 80%
Implanon® 0.05% 0.05% 84%
Female sterilization 0.5% 0.5% 100%
Male sterilization 0.15% 0.10% 100%
Emergency contraceptive pills*** Not applicable Not applicable Not applicable
Lactational amenorrhea methods††† Not applicable Not applicable Not applicable
Adapted from Trussell J. Contraceptive efficacy. In Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D. Contraceptive technology. 19th revised 
ed. New York, NY: Ardent Media; 2007.
 * Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an unintended pregnancy during 
the first year if they do not stop use for any other reason. Estimates of the probability of pregnancy during the first year of typical use for spermicides, with-
drawal, fertility awareness-based methods, the diaphragm, the male condom, the pill, and Depo-Provera are taken from the 1995 National Survey of Family 
Growth corrected for underreporting of abortion; see the text for the derivation of estimates for the other methods.
 † Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage 
who experience an unintended pregnancy during the first year if they do not stop use for any other reason. See the text for the derivation of the estimate 
for each method.
 § Among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 year.
 ¶ The percentages becoming pregnant in the typical use and perfect use columns are based on data from populations where contraception is not used 
and from women who cease using contraception to become pregnant. Of these, approximately 89% become pregnant within 1 year. This estimate was 
lowered slightly (to 85%) to represent the percentage who would become pregnant within 1 year among women now relying on reversible methods of 
contraception if they abandoned contraception altogether.
 ** Foams, creams, gels, vaginal suppositories, and vaginal film.
 †† The TwoDay and Ovulation methods are based on evaluation of cervical mucus. The Standard Days method avoids intercourse on cycle days 8–19.
 §§ With spermicidal cream or jelly.
 ¶¶ Without spermicides.
 *** Treatment initiated within 72 hours after unprotected intercourse reduces the risk for pregnancy by at least 75%. The treatment schedule is 1 dose within 
120 hours after unprotected intercourse and a second dose 12 hours after the first dose. Both doses of Plan B can be taken at the same time. Plan B (1 
dose is 1 white pill) is the only dedicated product specifically marketed for emergency contraception. The Food and Drug Administration has in addition 
declared the following 22 brands of oral contraceptives to be safe and effective for emergency contraception: Ogestrel or Ovral (1 dose is 2 white pills); 
Levlen or Nordette (1 dose is 4 light-orange pills); Cryselle, Levora, Low-Ogestrel, Lo/Ovral, or Quasence (1 dose is 4 white pills); Tri-Levlen or Triphasil 
(1 dose is 4 yellow pills); Jolessa, Portia, Seasonale, or Trivora (1 dose is 4 pink pills); Seasonique (1 dose is 4 light blue-green pills); Empresse (1 dose 
is 4 orange pills); Alesse, Lessina, or Levlite (1 dose is 5 pink pills); Aviane (1 dose is 5 orange pills); and Lutera (1 dose is 5 white pills).
 ††† Lactational amenorrhea method is a highly effective temporary method of contraception. However, to maintain effective protection against pregnancy, 
another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeding is reduced, bottle feeds 
are introduced, or the baby reaches 6 months of age.
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BOX 2. Conditions associated with increased risk for adverse 
health events as a result of unintended pregnancy
Breast cancer
Complicated valvular heart disease
Diabetes: insulin-dependent; with nephropathy/
retinopathy/neuropathy or other vascular disease; or 
of >20 years’ duration
Endometrial or ovarian cancer
Epilepsy
Hypertension (systolic >160 mm Hg or diastolic 
>100 mm Hg)
History of bariatric surgery within the past 2 years
HIV/AIDS
Ischemic heart disease
Malignant gestational trophoblastic disease
Malignant liver tumors (hepatoma) and 
hepatocellular carcinoma of the liver
Peripartum cardiomyopathy
Schistosomiasis with fibrosis of the liver
Severe (decompensated) cirrhosis
Sickle cell disease
Solid organ transplantation within the past 2 years
Stroke
Systemic lupus erythematosus
Thrombogenic mutations
Tuberculosis
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Appendix A
Summary of Changes to the World Health Organization Medical Eligibility 
Criteria for Contraceptive Use, 4th Edition, to Create the U.S. Medical 
Eligibility Criteria for Contraceptive Use, 2010
TABLE 1. Summary of changes in classifications from WHO Medical Eligibility Criteria for Contraceptive Use, 4th edition*†
Condition COC/P/R POP DMPA Implants LNG-IUD Cu-IUD Clarification
Breastfeeding The US Department of Health 
and Human Services recom-
mends that infants be exclusively 
breastfed during the first 4–6 
months of life, preferably for a 
full 6 months. Ideally, breastfeed-
ing should continue through the 
first year of life (1). {Not included 
in WHO MEC}
a. <1 mo postpartum {WHO: 
<6 wks postpartum}
3§ {4} 2§ {3} 2§ {3} 2§ {3}
b. 1 mo to <6 mos {WHO: ≥6 
wks to <6 mos postpartum}
2§ {3}
Postpartum (in breastfeeding 
or nonbreastfeeding women), 
including post caesarean 
section
a. <10 min after delivery of 
the placenta {WHO: <48 
hrs, including insertion im-
mediately after delivery of 
the placenta}
2 {1 if not 
breastfeed-
ing and 3 if 
breastfeeding}
b. 10 min after delivery of the 
placenta to <4 wks {WHO: 
≥48 hrs to <4 wks}
2 {3} 2{3}
Deep venous thrombosis 
(DVT)/pulmonary embolism 
(PE)
a. History of DVT/PE, not on 
anticoagulant therapy
ii. Lower risk for recurrent 
DVT/PE (no risk factors)
3 {4}
b. Acute DVT/PE 2 {3} 2 {3} 2 {3} 2 {3} 2 {1}
c. DVT/PE and established on 
anticoagulant therapy for at 
least 3 mos
The classification additions, deletions, and modifications 
from the World Health Organization (WHO) Medical 
Eligibility Criteria for Contraceptive Use, 4th Edition, are 
summarized below (Tables 1–3). For conditions for which 
BOX. Categories for Classifying Hormonal Contraceptives and Intrauterine Devices
1 = A condition for which there is no restriction for the use of the contraceptive method.
2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.
3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.
4 = A condition that represents an unacceptable health risk if the contraceptive method is used.
classification changed for ≥1 methods or the condition descrip-
tion underwent a major modification, WHO conditions and 
recommendations appear in curly brackets.
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TABLE 1. (Continued) Summary of changes in classifications from WHO Medical Eligibility Criteria for Contraceptive Use, 
4th edition*†
Condition COC/P/R POP DMPA Implants LNG-IUD Cu-IUD Clarification
i. Higher risk for recurrent 
DVT/PE (≥1 risk factors)
2 {1}
•	Known	thrombophilia,	
including 
antiphospholipid 
syndrome
•	Active	cancer	
(metastatic, on therapy, 
or within 6 mos after 
clinical remission), 
excluding non-
melanoma skin cancer
•	History	of	recurrent	
DVT/PE
ii. Lower risk for recurrent 
DVT/PE (no risk factors) 
3§ {4} 2 {1} Women on anticoagulant therapy 
are at risk for gynecologic com-
plications of therapy such as 
hemorrhagic ovarian cysts and 
severe menorrhagia. Hormonal 
contraceptive methods can be of 
benefit in preventing or treating 
these complications. When a 
contraceptive method is used 
as a therapy, rather than solely 
to prevent pregnancy, the risk/
benefit ratio may be different and 
should be considered on a case-
by-case basis. {Not included in 
WHO MEC}
Valvular heart disease
b. Complicated¶ (pulmonary 
hypertension, risk for 
atrial fibrillation, history 
of subacute bacterial 
endocarditis)
1 {2} 1 {2}
Ovarian cancer¶ 1 {Initiation = 3, 
Continuation = 2}
1 {Initiation = 3, 
Continuation = 2}
Uterine fibroids 2 {1 if no uterine 
distortion and 4 if 
uterine distortion 
is present}
2 {1 if no uterine 
distortion and 4 if 
uterine distortion is 
present}
* For conditions for which classification changed for ≥1 methods or the condition description underwent a major modification, WHO conditions and recom-
mendations appear in curly brackets.
† Abbreviations: WHO = World Health Organization; COC = combined oral contraceptive; P = combined hormonal contraceptive patch; R = combined 
hormonal vaginal ring; POP = progestin-only pill; DMPA = depot medroxyprogesterone acetate; LNG-IUD = levonorgestrel-releasing intrauterine device; 
Cu-IUD = copper intrauterine device; DVT = deep venous thrombosis; PE = pulmonary embolism; VTE = venous thromboembolism.
§ Consult the clarification column for this classification. 
¶ Condition that exposes a women to increased risk as a result of unintended pregnancy.
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TABLE 2. Summary of recommendations for medical conditions added to the U.S. Medical Eligibility Criteria for Contraceptive Use*
Condition COC/P/R POP DMPA Implants LNG-IUD Cu-IUD Clarification
History of bariatric surgery†
a. Restrictive procedures: decrease storage 
capacity of the stomach (vertical banded 
gastroplasty, laparoscopic adjustable 
gastric band, laparoscopic sleeve 
gastrectomy)
1 1 1 1 1 1
b. Malabsorptive procedures: decrease 
absorption of nutrients and calories 
by shortening the functional length of 
the small intestine (Roux-en-Y gastric 
bypass, biliopancreatic diversion)
COCs: 3 
P/R: 1
3 1 1 1 1
Peripartum cardiomyopathy†
a. Normal or mildly impaired cardiac 
function (New York Heart Association 
Functional Class I or II: patients with no 
limitation of activities or patients with 
slight, mild limitation of activity) (2)
i <6 mos 4 1 1 1 2 2
ii ≥6 mos 3 1 1 1 2 2
b. Moderately or severely impaired cardiac 
function (New York Heart Association 
Functional Class III or IV: patients with 
marked limitation of activity or patients 
who should be at complete rest) (2)
4 2 2 2 2 2
Rheumatoid arthritis Initiation
Continua-
tion Initiation
Continua-
tion
a. On immunosuppressive therapy 2 1 2/3§ 1 2 1 2 1 DMPA use among women on long-term corti-
costeroid therapy with a history of, or risk factors 
for, nontraumatic fractures is classified as Cat-
egory 3. Otherwise, DMPA use for women with 
rheumatoid arthritis is classified as Category 2.
b. Not on immunosuppressive therapy 2 1 2 1 1 1
Endometrial hyperplasia 1 1 1 1 1 1
Inflammatory bowel disease (IBD) 
(ulcerative colitis, Crohn disease)
2/3§ 2 2 1 1 1 For women with mild IBD, with no other risk 
factors for VTE, the benefits of COC/P/R use 
generally outweigh the risks (Category 2). 
However, for women with IBD with increased 
risk for VTE (e.g., those with active or extensive 
disease, surgery, immobilization, corticosteroid 
use, vitamin deficiencies, fluid depletion), the 
risks for COC/P/R use generally outweigh the 
benefits (Category 3).
Solid organ transplantation†
Initiation
Continua-
tion Initiation
Continua-
tion
a. Complicated: graft failure (acute or 
chronic), rejection, cardiac allograft 
vasculopathy
4 2 2 2 3 2 3 2
b. Uncomplicated 2§ 2 2 2 2 2 Women with Budd-Chiari syndrome should not 
use COC/P/R because of the increased risk for 
thrombosis.
* Abbreviations: COC = combined oral contraceptive; P = combined hormonal contraceptive patch; R = combined hormonal vaginal ring: POP = progestin-only pill; DMPA = depot 
medroxyprogesterone acetate; LNG-IUD = levonorgestrel-releasing intrauterine device; Cu-IUD = copper intrauterine device; IBD = inflammatory bowel disease; VTE = venous 
thromboembolism.
† Condition that exposes a women to increased risk as a result of unintended pregnancy.
§ Consult the clarification column for this classification.
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TABLE 3. Summary of additional changes to the U.S. Medical Eligibility Criteria for Contraceptive Use
Condition/Contraceptive method Change
Emergency contraceptive pills History of bariatric surgery, rheumatoid arthritis, inflammatory bowel disease, and solid organ transplantation 
were added to Appendix D and given a Category 1. 
Barrier methods For 6 conditions—history of bariatric surgery, peripartum cardiomyopathy, rheumatoid arthritis, endometrial 
hyperplasia, inflammatory bowel disease, and solid organ transplantation—the barrier methods are classified 
as Category 1.
Sterilization In general, no medical conditions would absolutely restrict a person’s eligibility for sterilization. 
Recommendations from the World Health Organization (WHO) Medical Eligibility Criteria for Contraceptive 
Use about specific settings and surgical procedures for sterilization are not included here. The guidance has 
been replaced with general text on sterilization.
Other deleted items Guidance for combined injectables, levonorgestrel implants, and norethisterone enanthate has been re-
moved because these methods are not currently available in the United States.
Guidance for “blood pressure measurement unavailable” and “history of hypertension, where blood pressure 
CANNOT be evaluated (including hypertension in pregnancy)” has been removed.
Unintended pregnancy and increased 
health risk
The following conditions have been added to the WHO list of conditions that expose a woman to increased 
risk as a result of unintended pregnancy: history of bariatric surgery within the past 2 years, peripartum car-
diomyopathy, and receiving a solid organ transplant within 2 years.
References
1. Office on Women’s Health, US Department of Health and Human 
Services. HHS blueprint for action on breastfeeding. Washington, DC: 
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and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. 
Boston, MA: Little, Brown & Co; 1994.
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Combined hormonal contraceptives (CHCs) include low-
dose (containing ≤35 μg ethinyl estradiol [EE]) combined oral 
contraceptives (COCs), the combined hormonal patch, and 
the combined vaginal ring. The combined hormonal patch and 
vaginal ring are relatively new contraceptive methods. Limited 
information is available about the safety of these methods 
among women with specific medical conditions. Moreover, 
epidemiologic data on the long-term effects of the combined 
hormonal patch and the vaginal ring were not available for 
review. Evidence indicates that the combined hormonal patch 
and the combined vaginal ring provide comparable safety 
and pharmacokinetic profiles to COCs with similar hormone 
formulations (1–33). Pending further studies, the evidence 
available for recommendations about COCs applies to the 
recommendations for the combined hormonal patch and vagi-
nal ring. Therefore, the patch and ring should have the same 
categories (Box) as COCs, except where noted. The assigned 
categories should, therefore, be considered a preliminary, best 
judgement, which will be reevaluated as new data become 
available. CHCs do not protect against sexually transmitted 
infections (STIs) or human immunodeficiency virus (HIV).
Appendix B
 Classifications for Combined Hormonal Contraceptives
BOX. Categories for Classifying Combined Hormonal Contraceptives
1 = A condition for which there is no restriction for the use of the contraceptive method.
2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.
3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.
4 = A condition that represents an unacceptable health risk if the contraceptive method is used.
TABLE. Classifications for combined hormonal contraceptives, including pill, patch, and ring*†
Condition Category Clarifications/Evidence/Comments
Personal Characteristics and Reproductive History
Pregnancy Not applicable Clarification: Use of COCs, P, or R is not required. There is no known harm to the woman, the course of 
her pregnancy, or the fetus if COCs, P, or R are inadvertently used during pregnancy.
Age
a. Menarche to <40 yrs 1 Evidence: Adolescents using 20 μg EE-containing COCs have lower BMD than do nonusers, and higher 
dose-containing COCs have little to no effect. (34–41). In premenopausal adult women, COC use has little 
to no effect on bone health while appearing to preserve bone mass in perimenopausal women (26,42–90). 
Postmenopausal women who have ever used COCs have similar BMD to postmenopausal women who 
have never used COCs (54,58,68,81,91–110). BMD in adolescent or premenopausal women may not ac-
curately predict postmenopausal fracture risk (109,111–122).
Comment: The risk for cardiovascular disease increases with age and might increase with CHC use. In the 
absence of other adverse clinical conditions, CHCs can be used until menopause.
b. ≥40 yrs 2
Parity
a. Nulliparous 1
b. Parous 1
Breastfeeding Clarification: The U.S. Department of Health and Human Services recommends that infants be exclusively 
breastfed during the first 4–6 months of life, preferably for a full 6 months. Ideally, breastfeeding should 
continue through the first year of life (123).
Evidence: Clinical studies demonstrate conflicting results about effects on milk volume in women exposed 
to COCs during lactation; no consistent effect on infant weight has been reported. Adverse health outcomes 
or manifestations of exogenous estrogen in infants exposed to CHCs through breast milk have not been 
demonstrated (124–133). In general, these studies are of poor quality, lack standard definitions of breast-
feeding or outcome measures, and have not included premature or ill infants. Theoretical concerns about 
effects of CHCs on breast milk production are greater in the early postpartum period when milk flow is being 
established.
a. <1 mo postpartum 3
b. 1 mo to <6 mos postpartum 2
c. ≥6 mos postpartum 2
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TABLE. (Continued) Classifications for combined hormonal contraceptives, including pill, patch, and ring*†
Condition Category Clarifications/Evidence/Comments
Postpartum (in nonbreastfeeding 
women)
a. <21 days 3 Comment: Theoretical concern exists about the association between CHC use up to 3 weeks postpartum 
and risk for thrombosis in the mother. Blood coagulation and fibrinolysis are essentially normalized by 3 
weeks postpartum.
b. ≥21 days 1
Postabortion Clarification: COCs, P, or R may be started immediately postabortion.
a. First trimester 1 Evidence: Women who started taking COCs immediately after first trimester medical or surgical abortion 
did not experience more side effects or adverse vaginal bleeding outcomes or clinically significant changes 
in coagulation parameters than did women who used a placebo, an IUD, a nonhormonal contraceptive 
method, or delayed COC initiation (134–140). Limited evidence on women using the ring immediately after 
first trimester medical or surgical abortion found no serious adverse events and no infection related to use 
of the combined vaginal contraceptive ring during 3 cycles of follow-up postabortion (141).
b. Second trimester 1
c. Immediate postseptic abortion 1
Past ectopic pregnancy 1 Comment: The risk for future ectopic pregnancy is increased among women who have had an ectopic 
pregnancy in the past. CHCs protect against pregnancy in general, including ectopic gestation.
History of pelvic surgery 1
Smoking
a. Age <35 yrs 2 Evidence: COC users who smoked were at increased risk for cardiovascular diseases, especially myocar-
dial infarction, than those who did not smoke. Studies also showed an increased risk for myocardial infarc-
tion with increasing number of cigarettes smoked per day (142–153).
b. Age ≥35 yrs
 i. <15 Cigarettes/day 3
 ii. ≥15 Cigarettes/day 4
Obesity
a. ≥30 kg/m2 BMI 2 Evidence: Obese women who use COCs are more likely than obese women who do not use COCs to 
experience VTE. The absolute risk for VTE in healthy women of reproductive age is small. Limited evidence 
suggests that obese women who use COCs do not have a higher risk for acute myocardial infarction or 
stroke than do obese nonusers (147,153–159). Limited evidence is inconsistent about whether COC ef-
fectiveness varies by body weight or BMI (160–165). Limited evidence suggests obese women are no more 
likely to gain weight after 3 cycles of the vaginal ring or COC than overweight or normal weight women. 
A similar weight gain during the 3 months was noted between the COC group and the vaginal ring group 
across all BMI categories (166). The effectiveness of the patch decreased among women who weighed >90 
kg; however, no association was found between pregnancy risk and BMI (18).
b. Menarche to <18 yrs and 
≥30 kg/m2 BMI
2
History of bariatric surgery§
a. Restrictive procedures: decrease 
storage capacity of the stomach 
(vertical banded gastroplasty, 
laparoscopic adjustable gastric band, 
laparoscopic sleeve gastrectomy)
1 Evidence: Limited evidence demonstrated no substantial decrease in effectiveness of oral contraceptives 
among women who underwent laparoscopic placement of an adjustable gastric band (167).
b. Malabsorptive procedures: decrease 
absorption of nutrients and calories 
by shortening the functional length of 
the small intestine (Roux-en-Y gas-
tric bypass, biliopancreatic diversion)
COCs: 3
P/R: 1
Evidence: Limited evidence demonstrated no substantial decrease in effectiveness of oral contraceptives 
among women who underwent a biliopancreatic diversion (168); however, evidence from pharmacokinetic 
studies reported conflicting results of oral contraceptive effectiveness among women who underwent a 
jejunoileal bypass (169,170).
Comment: Bariatric surgical procedures involving a malabsorptive component have the potential to de-
crease oral contraceptive effectiveness, perhaps further decreased by postoperative complications, such as 
long-term diarrhea and/or vomiting.
Cardiovascular Disease
Multiple risk factors for arte-
rial cardiovascular disease (such 
as older age, smoking, diabetes, and 
hypertension)
3/4 Clarification: When a woman has multiple major risk factors, any of which alone would substantially 
increase her risk for cardiovascular disease, use of COCs, P, or R might increase her risk to an unaccept-
able level. However, a simple addition of categories for multiple risk factors is not intended; for example, a 
combination of two risk factors assigned a category 2 might not necessarily warrant a higher category.
Hypertension
For all categories of hypertension, classifications are based on the assumption that no other risk factors exist for cardiovascular disease. When multiple risk factors do exist, 
risk for cardiovascular disease might increase substantially. A single reading of blood pressure level is not sufficient to classify a woman as hypertensive.
a. Adequately controlled hypertension 3 Clarification: Women adequately treated for hypertension are at reduced risk for acute myocardial 
infarction and stroke compared with untreated women. Although no data exist, COC, P, or R users with 
adequately controlled and monitored hypertension should be at reduced risk for acute myocardial infarction 
and stroke compared with untreated hypertensive COC, P, or R users.
b. Elevated blood pressure levels 
(properly taken measurements)
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TABLE. (Continued) Classifications for combined hormonal contraceptives, including pill, patch, and ring*†
Condition Category Clarifications/Evidence/Comments
i. Systolic 140–159 mm Hg or 
diastolic 90–99 mm Hg
3 Evidence: Among women with hypertension, COC users were at higher risk than nonusers for 
stroke, acute myocardial infarction, and peripheral arterial disease (142,144,151–153,155,171–186). 
Discontinuation of COCs in women with hypertension might improve blood pressure control (187).ii. Systolic ≥160 mm Hg or diastolic 
≥100 mm Hg§
4
c. Vascular disease 4
History of high blood pressure during 
pregnancy (where current blood pres-
sure is measurable and normal)
2 Evidence: Women with a history of high blood pressure in pregnancy, who also used COCs, had a 
higher risk for myocardial infarction and VTE than did COC users who did not have a history of high blood 
pressure during pregnancy. The absolute risks for acute myocardial infarction and VTE in this population 
remained small (153,172,184–186,188–193).
Deep venous thrombosis (DVT)/ 
Pulmonary embolism (PE)
a. History of DVT/PE, not on anticoagu-
lant therapy
 i. Higher risk for recurrent DVT/PE 
(≥1 risk factors)
	 •	 History	of	estrogen-associated	
DVT/PE
	 •	 Pregnancy-associated	DVT/PE
	 •	 Idiopathic	DVT/PE
	 •	 Known	thrombophilia,	including	
antiphospholipid syndrome
	 •	 Active	cancer	(metastatic,	on	
therapy, or within 6 mos after 
clinical remission), excluding 
non-melanoma skin cancer
	 •	 History	of	recurrent	DVT/PE
4
 ii. Lower risk for recurrent DVT/PE 
(no risk factors)
3
b. Acute DVT/PE 4
c. DVT/PE and established on anti-
coagulant therapy for at least 3 mos
 i. Higher risk for recurrent DVT/PE 
(≥1 risk factors)
	 •	 Known	thrombophilia,	including	
antiphospholipid syndrome
	 •	 Active	cancer	(metastatic,	on	
therapy, or within 6 mos after 
clinical remission), excluding 
non-melanoma skin cancer
	 •	 History	of	recurrent	DVT/PE
4 Clarification: Women on anticoagulant therapy are at risk for gynecologic complications of therapy, such 
as hemorrhagic ovarian cysts and severe menorrhagia. Hormonal contraceptive methods can be of benefit 
in preventing or treating these complications. When a contraceptive method is used as a therapy, rather 
than solely to prevent pregnancy, the risk/benefit ratio might differ and should be considered on a case-by-
case basis.
 ii. Lower risk for recurrent DVT/PE 
(no risk factors)
3 Clarification: Women on anticoagulant therapy are at risk for gynecologic complications of therapy, such 
as hemorrhagic ovarian cysts and severe menorrhagia. Hormonal contraceptive methods can be of benefit 
in preventing or treating these complications. When a contraceptive method is used as a therapy, rather 
than solely to prevent pregnancy, the risk/benefit ratio may differ and should be considered on a case-by-
case basis.
d. Family history (first-degree relatives) 2 Comment: Some conditions that increase the risk for DVT/PE are heritable.
e. Major surgery
 i. With prolonged immobilization 4
 ii. Without prolonged immobilization 2
f. Minor surgery without immobilization 1
Known thrombogenic mutations§ 
(e.g., factor V Leiden; prothrombin muta-
tion; protein S, protein C, and antithrom-
bin deficiencies)
4 Clarification: Routine screening is not appropriate because of the rarity of the conditions and the high cost 
of screening.
Evidence: Among women with thrombogenic mutations, COC users had a 2-fold to 20-fold higher risk for 
thrombosis than did nonusers (159,194–216).
Superficial venous thrombosis
a. Varicose veins 1 Comment: Varicose veins are not risk factors for DVT/PE
b. Superficial thrombophlebitis 2
Current and history of ischemic heart 
disease§
4
Stroke§ (history of cerebrovascular 
accident) 
4
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TABLE. (Continued) Classifications for combined hormonal contraceptives, including pill, patch, and ring*†
Condition Category Clarifications/Evidence/Comments
Known hyperlipidemias 2/3 Clarification: Routine screening is not appropriate because of the rarity of the conditions and the high cost 
of screening. Although some types of hyperlipidemias are risk factors for vascular disease, the category 
should be assessed according to the type, its severity, and the presence of other cardiovascular risk 
factors. 
Valvular heart disease
a. Uncomplicated 2
b. Complicated§ (pulmonary hyperten-
sion, risk for atrial fibrillation, history 
of subacute bacterial endocarditis)
4 Comment: Among women with valvular heart disease, CHC use may further increase the risk for arterial 
thrombosis; women with complicated valvular heart disease are at greatest risk.
Peripartum cardiomyopathy§
a. Normal or mildly impaired car-
diac function (New York Heart 
Association Functional Class I or II: 
patients with no limitation of activities 
or patients with slight, mild limitation 
of activity) (217)
Evidence: No direct evidence exists about the safety of COCs/P/R among women with peripartum 
cardiomyopathy. Limited indirect evidence from noncomparative studies of women with cardiac disease 
demonstrated few cases of hypertension and transient ischemic attack in women with cardiac disease using 
COCs. No cases of heart failure were reported (218).
Comment: COCs might increase fluid retention in healthy women; fluid retention may worsen heart failure 
in women with peripartum cardiomyopathy. COCs might induce cardiac arrhythmias in healthy women; 
women with peripartum cardiomyopathy have a high incidence of cardiac arrhythmias.
 i. <6 mos 4
 ii. ≥6 mos 3
b. Moderately or severely impaired 
cardiac function (New York Heart 
Association Functional Class III or 
IV: patients with marked limitation of 
activity or patients who should be at 
complete rest) (217)
4 Evidence: No direct evidence exists about the safety of COCs/P/R among women with peripartum 
cardiomyopathy. Limited indirect evidence from noncomparative studies of women with cardiac disease 
demonstrated few cases of hypertension and transient ischemic attack in women with cardiac disease using 
COCs. No cases of heart failure were reported (218).
Comment: COCs might increase fluid retention in healthy women; fluid retention may worsen heart failure 
in women with peripartum cardiomyopathy. COCs might induce cardiac arrhythmias in healthy women; 
women with peripartum cardiomyopathy have a high incidence of cardiac arrhythmias.
Rheumatic Diseases
Systemic lupus erythematosus (SLE)§
Persons with SLE are at increased risk for ischemic heart disease, stroke, and VTE. Categories assigned to such conditions in the MEC should be the same for women with 
SLE who present with these conditions. For all categories of SLE, classifications are based on the assumption that no other risk factors for cardiovascular disease are pres-
ent; these classifications must be modified in the presence of such risk factors.
Many women with SLE can be considered good candidates for most contraceptive methods, including hormonal contraceptives (219–237).
a. Positive (or unknown) antiphospho-
lipid antibodies
4 Evidence: Antiphospholipid antibodies are associated with a higher risk for both arterial and venous throm-
bosis (238,239).
b. Severe thrombocytopenia 2
c. Immunosuppressive treatment 2
d. None of the above 2
Rheumatoid arthritis
a. On immunosuppressive therapy 2 Evidence: Limited evidence shows no consistent pattern of improvement or worsening of rheumatoid arthri-
tis with use of oral contraceptives (240–245), progesterone (246), or estrogen (247).b. Not on immunosuppressive therapy 2
Neurologic Conditions
Headaches Initiation ContinuationClarification: Classification depends on accurate diagnosis of those severe headaches that are migrainous 
and those headaches that are not. Any new headaches or marked changes in headaches should be evalu-
ated. Classification is for women without any other risk factors for stroke. Risk for stroke increases with age, 
hypertension and smoking.
a. Non-migrainous (mild or severe) 1 2
b. Migraine Evidence: Among women with migraine, women who also had aura had a higher risk for stroke than did 
those without aura (248–250). Women with a history of migraine who use COCs are about 2–4 times as 
likely to have an ischemic stroke as nonusers with a history of migraine (142,157,179,180,249-254).
Comment: Aura is a specific focal neurologic symptom. For more information about this and other diag-
nostic criteria, see: Headache Classification Subcommittee of the International Headache Society. The 
International Classification of Headache Disorders, 2nd ed. Cephalalgia. 2004;24(Suppl 1). Available http://
www.i-h-s.org/upload/ct_clas/ihc_II_main_no_print.pdf.
 i. Without aura
	 •	 Age	<35	yrs 2 3
	 •	 Age	≥35	yrs 3 4
 ii. With aura, at any age 4 4
Epilepsy§ 1 Clarification: If a woman is taking anticonvulsants, refer to the section on drug interactions. Certain anti-
convulsants lower COC effectiveness. The extent to which P or R use is similar to COC use in this regard 
remains unclear.
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TABLE. (Continued) Classifications for combined hormonal contraceptives, including pill, patch, and ring*†
Condition Category Clarifications/Evidence/Comments
Depressive Disorders
Depressive disorders 1 Clarification: The classification is based on data for women with selected depressive disorders. No data on 
bipolar disorder or postpartum depression were available. Drug interactions potentially can occur between 
certain antidepressant medications and hormonal contraceptives.
Evidence: COC use did not increase depressive symptoms in women with depression compared with base-
line or with nonusers with depression (255–264).
Reproductive Tract Infections and Disorders
Vaginal bleeding patterns
a. Irregular pattern without heavy 
bleeding
1 Comment: Irregular menstrual bleeding patterns are common among healthy women.
b. Heavy or prolonged bleeding (in-
cludes regular and irregular patterns)
1 Clarification: Unusually heavy bleeding should raise suspicion of a serious underlying condition.
Evidence: A Cochrane Collaboration Review identified 1 randomized controlled trial evaluating the ef-
fectiveness of COC use compared with naproxen and danazol in treating menorrhagic women. Women with 
menorrhagia did not report worsening of the condition or any adverse events related to COC use (265).
Unexplained vaginal bleeding 
(suspicious for serious condition)
Before evaluation 2 Clarification: If pregnancy or an underlying pathological condition (such as pelvic malignancy) is sus-
pected, it must be evaluated and the category adjusted after evaluation. 
Comment: No conditions that cause vaginal bleeding will be worsened in the short term by use of CHCs.
Endometriosis 1 Evidence: A Cochrane Collaboration Review identified 1 randomized controlled trial evaluating the effec-
tiveness of COC use compared with a gonadotropin-releasing hormone analogue in treating the symptoms 
of endometriosis. Women with endometriosis did not report worsening of the condition or any adverse 
events related to COC use (266).
Benign ovarian tumors (including cysts) 1
Severe dysmenorrhea 1 Evidence: Risk for side effects with COC use was not higher among women with dysmenorrhea than 
among women not using COCs. Some COC users had a reduction in pain and bleeding (267,268).
Gestational trophoblastic disease
a. Decreasing or undetectable β–hCG 
levels
1 Evidence: After molar pregnancy evacuation, the balance of evidence found COC use did not increase 
the risk for postmolar trophoblastic disease, and β-hCG levels regressed more rapidly in some COC users 
than in nonusers (269–275). Limited evidence suggests that use of COCs during chemotherapy does not 
significantly affect the regression or treatment of postmolar trophoblastic disease compared with women 
who used a nonhormonal contraceptive method or DMPA during chemotherapy (276).
b. Persistently elevated β-hCG levels or 
malignant disease§
1
Cervical ectropion 1 Comment: Cervical ectropion is not a risk factor for cervical cancer, and restriction of CHC use is 
unnecessary.
Cervical intraepithelial neoplasia 2 Evidence: Among women with persistent HPV infection, long-term COC use (≥5 years) might increase 
the risk for carcinoma in situ and invasive carcinoma (21,277). Limited evidence on women with low-grade 
squamous intraepithelial lesions found use of the vaginal ring did not worsen the condition (21).
Cervical cancer (awaiting treatment) 2 Comment: Theoretical concern exists that CHC use might affect prognosis of the existing disease. While 
awaiting treatment, women may use CHCs. In general, treatment of this condition can render a woman 
sterile.
Breast Disease
a. Undiagnosed mass 2 Clarification: The woman should be evaluated as early as possible.
b. Benign breast disease 1
c. Family history of cancer 1 Evidence: Women with breast cancer susceptibility genes (such as BRCA1 and BRCA2) have a higher 
baseline risk for breast cancer than do women without these genes. The baseline risk for breast cancer is 
also higher among women with a family history of breast cancer than among those who do not have such 
a history. However, current evidence does not suggest that the increased risk for breast cancer among 
women with either a family history of breast cancer or breast cancer susceptibility genes is modified by the 
use of COCs (278–295).
d. Breast cancer§
Comment: Breast cancer is a hormonally sensitive tumor, and the prognosis for women with current or 
recent breast cancer might worsen with CHC use.
 i. Current 4
 ii. Past and no evidence of current 
disease for 5 yrs
3
Endometrial hyperplasia
1
Endometrial cancer§
1 Comment: COC use reduces the risk for endometrial cancer; whether P or R use reduces the risk for 
endometrial cancer is not known. While awaiting treatment, women may use COCs, P, or R. In general, 
treatment of this condition renders a woman sterile.
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TABLE. (Continued) Classifications for combined hormonal contraceptives, including pill, patch, and ring*†
Condition Category Clarifications/Evidence/Comments
Ovarian cancer§ 1 Comment: COC use reduces the risk for ovarian cancer; whether P or R use reduces the risk for ovarian 
cancer is not known. While awaiting treatment, women may use COCs, P, or R. In general, treatment of this 
condition can render a woman sterile.
Uterine fibroids 1 Comment: COCs do not appear to cause growth of uterine fibroids, and P and R also are not expected to 
cause growth.
Pelvic inflammatory disease (PID)
a. Past PID (assuming no current risk 
factors for STIs)
Comment: COCs might reduce the risk for PID among women with STIs but do not protect against HIV 
or lower genital tract STIs. Whether use of P or R reduces the risk for PID among women with STIs is 
unknown, but they do not protect against HIV or lower genital tract STIs.
 i. With subsequent pregnancy 1
 ii. Without subsequent pregnancy 1
b. Current PID 1
STIs
a. Current purulent cervicitis or chla-
mydial infection or gonorrhea
1
b. Other STIs (excluding HIV and 
hepatitis)
1
c. Vaginitis (including Trichomonas 
vaginalis and bacterial vaginosis)
1
d. Increased risk for STIs 1 Evidence: Evidence suggests that chlamydial cervicitis may be increased among COC users at high risk 
for STIs. For other STIs, there is either evidence of no association between COC use and STI acquisition or 
too limited evidence to draw any conclusions (296–376).
HIV/AIDS
High risk for HIV 1 Evidence: The balance of the evidence suggests no association between oral contraceptive use and HIV 
acquisition, although findings from studies conducted among higher risk populations have been inconsistent 
(377–415).
HIV infection§ 1 Evidence: Most studies suggest no increased risk for HIV disease progression with hormonal contraceptive 
use, as measured by changes in CD4 cell count, viral load, or survival. Studies observing that women with 
HIV who use hormonal contraception have increased risks of acquiring STIs are generally consistent with 
reports among uninfected women. One direct study found no association between hormonal contraceptive 
use and an increased risk for HIV transmission to uninfected partners; several indirect studies reported 
mixed results about whether hormonal contraception is associated with increased risk for HIV-1 DNA or 
RNA shedding from the genital tract (377,416–432).
AIDS§ 1 Clarification: Drug interactions may occur between hormonal contraceptives and ARV therapy; refer to the 
section on drug interactions.
Other Infections
Schistosomiasis
a. Uncomplicated 1 Evidence: Among women with uncomplicated schistosomiasis, COC use had no adverse effects on liver 
function (433–439).
b. Fibrosis of liver§ (if severe, see 
cirrhosis)
1
Tuberculosis§ Clarification: If a woman is taking rifampicin, refer to the section on drug interactions. Rifampicin is likely to 
decrease COC effectiveness. The extent to which P or R use is similar to COC use in this regard remains 
unclear.
a. Nonpelvic 1
b. Pelvic 1
Malaria 1
Endocrine Conditions
Diabetes
a. History of gestational disease 1 Evidence: The development of noninsulin-dependant diabetes in women with a history of gestational 
diabetes is not increased by use of COCs (440–447). Likewise, lipid levels appear to be unaffected by COC 
use (448–450).
b. Nonvascular disease Evidence: Among women with insulin- or noninsulin-dependent diabetes, COC use had limited effect on 
daily insulin requirements and no effect on long-term diabetes control (e.g., glycosylated hemoglobin levels) 
or progression to retinopathy. Changes in lipid profile and hemostatic markers were limited, and most 
changes remained within normal values (451–460).
 i. Noninsulin-dependent 2
 ii. Insulin-dependent§ 2
c. Nephropathy/retinopathy/ 
neuropathy§
3/4 Clarification: The category should be assessed according to the severity of the condition.
d. Other vascular disease or diabetes of 
>20 yrs’ duration§
3/4 Clarification: The category should be assessed according to the severity of the condition.
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TABLE. (Continued) Classifications for combined hormonal contraceptives, including pill, patch, and ring*†
Condition Category Clarifications/Evidence/Comments
Thyroid disorders
a. Simple goiter 1
b. Hyperthyroid 1
c. Hypothyroid 1
Gastrointestinal Conditions
Inflammatory bowel disease (IBD) 
(ulcerative colitis, Crohn disease)
2/3 Clarification: For women with mild IBD and no other risk factor for VTE, the benefits of COC/P/R use 
generally outweigh the risks (Category 2). However, for women with IBD who are at increased risk for VTE 
(e.g., those with active or extensive disease, surgery, immobilization, corticosteroid use, vitamin deficien-
cies, or fluid depletion), the risks of COC/P/R use generally outweigh the benefits (Category 3).
Evidence: Risk for disease relapse was not significantly higher among women with IBD using oral contra-
ceptives (most studies did not specify formulation) than among nonusers (461–465).
Absorption of COCs among women with mild ulcerative colitis and no or small ileal resections was similar to 
the absorption among healthy women (466,467). Findings might not apply to women with Crohn disease or 
more extensive bowel resections.
No data exist that evaluate the increased risk for VTE among women with IBD using COCs/P/R. However, 
women with IBD are at higher risk than unaffected women for VTE (468).
Gallbladder disease
a. Symptomatic Comment: COCs, P, or R might cause a small increased risk for gallbladder disease. COCs, P, or R might 
worsen existing gallbladder disease. i. Treated by cholecystectomy 2
 ii. Medically treated 3
 iii. Current 3
b. Asymptomatic 2
History of cholestasis
a. Pregnancy-related 2 Comment: History of pregnancy-related cholestasis might predict an increased risk for COC-related 
cholestasis.
b. Past COC-related 3 Comment: History of COC-related cholestasis predicts an increased risk with subsequent COC use.
Viral hepatitis Initiation Continuation
a. Acute or flare 3/4 2 Clarification for initiation: The category should be assessed according to the severity of the condition.
Evidence: Data suggest that in women with chronic hepatitis, COC use does not increase the rate or sever-
ity of cirrhotic fibrosis, nor does it increase the risk for hepatocellular carcinoma (469,470). For women who 
are carriers, COC use does not appear to trigger liver failure or severe dysfunction (471-473). Evidence is 
limited for COC use during active hepatitis (474).
b. Carrier 1 1
c. Chronic 1 1
Cirrhosis
a. Mild (compensated) 1
b. Severe§ (decompensated) 4
Liver tumors
a. Benign Evidence: Limited direct evidence suggests that hormonal contraceptive use does not influence either 
progression or regression of liver lesions among women with focal nodular hyperplasia (475,476). i. Focal nodular hyperplasia 2
 ii. Hepatocellular adenoma§ 4
b. Malignant§ (hepatoma) 4
Anemias
Thalassemia 1 Comment: Anecdotal evidence from countries where thalassemia is prevalent indicates that COC use does 
not worsen the condition.
Sickle cell disease§ 2
Iron deficiency anemia 1 Comment: CHC use may decrease menstrual blood loss.
Solid Organ Transplantation
Solid organ transplantation§
a. Complicated: graft failure (acute or 
chronic), rejection, cardiac allograft 
vasculopathy
4 Evidence: Limited evidence of COC and P users indicated no overall changes in biochemical measures. 
However, one study reported discontinuations of COC use in 2 (8%) of 26 women as a result of serious 
medical complications, and in one case report, a woman developed cholestasis associated with high-dose 
COC use (477–480).
b. Uncomplicated 2 Clarification: Women with Budd-Chiari syndrome should not use COC/P/R because of the increased risk 
for thrombosis.
Evidence: Limited evidence of COC and P users indicated no overall changes in biochemical measures. 
However, one study reported discontinuations of COC use in 2 (8%) of 26 women as a result of serious 
medical complications, and in one case report, a woman developed cholestasis associated with high-dose 
COC use (477–480).
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TABLE. (Continued) Classifications for combined hormonal contraceptives, including pill, patch, and ring*†
Condition Category Clarifications/Evidence/Comments
Drug Interactions
Antiretroviral (ARV) therapy Clarification: ARV drugs have the potential to either decrease or increase the bioavailability of steroid 
hormones in hormonal contraceptives. Limited data (summarized in Appendix M) suggest potential drug 
interactions between many ARV drugs (particularly some non-NNRTIs and ritonavir-boosted protease 
inhibitors) and hormonal contraceptives. These interactions might alter the safety and effectiveness of both 
the hormonal contraceptive and the ARV drug. Thus, if a woman on ARV treatment decides to initiate or 
continue hormonal contraceptive use, the consistent use of condoms is recommended to both prevent HIV 
transmission and compensate for any possible reduction in the effectiveness of the hormonal contraceptive. 
When a COC is chosen, a preparation containing a minimum of 30 µg EE should be used.
a. Nucleoside reverse transcriptase 
inhibitors (NRTIs) 
1
b. Non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs)
2
c. Ritonavir-boosted protease inhibitors 3
Anticonvulsant therapy Clarification: Although the interaction of certain anticonvulsants with COCs, P, or R is not harmful to 
women, it is likely to reduce the effectiveness of COCs, P, or R. Use of other contraceptives should be en-
couraged for women who are long-term users of any of these drugs. When a COC is chosen, a preparation 
containing a minimum of 30 µg EE should be used.
Evidence: Use of certain anticonvulsants might decrease the effectiveness of COCs (481–484).
a. Certain anticonvulsants (phenytoin, 
carbamazepine, barbiturates, primi-
done, topiramate, oxcarbazepine) 
3
b. Lamotrigine 3 Clarification: The recommendation for lamotrigine applies only for situations where lamotrigine mono-
therapy is taken concurrently with COCs. Anticonvulsant treatment regimens that combine lamotrigine and 
nonenzyme-inducing antiepileptic drugs (such as sodium valproate) do not interact with COCs. 
Evidence: Pharmacokinetic studies show levels of lamotrigine decrease significantly during COC use 
(485–489). Some women who used both COCs and lamotrigine experienced increased seizure activity in 
one trial (485).
Antimicrobial therapy
a. Broad-spectrum antibiotics 1 Evidence: Most broad-spectrum antibiotics do not affect the contraceptive effectiveness of COCs(490–
526), P (527) or R (528).
b. Antifungals 1 Evidence: Studies of antifungal agents have shown no clinically significant pharmacokinetic interactions 
with COCs (529–538) or R (539).
c. Antiparasitics 1 Evidence: Studies of antiparasitic agents have shown no clinically significant pharmacokinetic interactions 
with COCs (433,540–544).
d. Rifampicin or rifabutin therapy 3 Clarification: Although the interaction of rifampicin or rifabutin therapy with COCs, P, or R is not harmful 
to women, it is likely to reduce the effectiveness of COCs, P, or R. Use of other contraceptives should be 
encouraged for women who are long-term users of either of these drugs. When a COC is chosen, a prepa-
ration containing a minimum of 30 µg EE should be used.
Evidence: The balance of the evidence suggests that rifampicin reduces the effectiveness of COCs 
(545–560). Data on rifabutin are limited, but effects on metabolism of COCs are less than with rifampicin, 
and small studies have not shown evidence of ovulation (547,554).
* Abbreviations: STI = sexually transmitted infection; HIV = human immunodeficiency virus; COC = combined oral contraceptive; P = patch; R = ring; EE = ethinyl estradiol; 
BMD = bone mineral density; CHC = combined hormonal contraceptive; IUD = intrauterine device; VTE = venous thromboembolism; BMI = body mass index; DVT = deep 
venous thrombosis; PE = pulmonary embolism; SLE = systemic lupus erythematosus; MEC = Medical Eligibility Criteria; hCG = human chorionic gonadotropin; DMPA = depot 
medroxyprogesterone acetate; HPV = human papillomavirus; PID = pelvic inflammatory disease; AIDS = acquired immunodeficiency syndrome; ARV = antiretroviral; IBD = 
inflammatory bowel disease; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor. 
† COCs/P/R do not protect against STI/HIV. If risk for STI/HIV (including during pregnancy or postpartum) exists, the correct and consistent use of condoms is recommended, 
either alone or with another contraceptive method. Consistent and correct use of the male latex condom reduces the risk for STI/HIV transmission.
§ Condition that exposes a woman to increased risk as a result of unintended pregnancy.
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Appendix C
 Classifications for Progestin-Only Contraceptives 
Classifications for progestin-only contraceptives (POCs)
include those for progestin-only pills, depot medroxyproges-
terone acetate, and progestin-only implants (Box). POCs do 
BOX. Categories for Classifying Progestin-Only Contraceptives
1 = A condition for which there is no restriction for the use of the contraceptive method.
2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.
3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.
4 = A condition that represents an unacceptable health risk if the contraceptive method is used.
TABLE. Classifications for progestin-only contraceptives, including progestin-only pills, DMPA, and implants*†
Condition
Category
Clarifications/Evidence/CommentsPOP DMPA Implants
Personal Characteristics and Reproductive History
Pregnancy Not applicable Not applicable Not applicable Clarification: Use of POCs is not required. There is no 
known harm to the woman, the course of her pregnancy, or 
the fetus if POCs are inadvertently used during pregnancy. 
However, the relation between DMPA use during pregnancy 
and its effects on the fetus remains unclear.
Age
a. Menarche to <18 yrs 1 2 1 Evidence: Most studies have found that women lose 
BMD while using DMPA but regain BMD after discontinu-
ing DMPA. It is not known whether DMPA use among 
adolescents affects peak bone mass levels or whether adult 
women with long duration of DMPA use can regain BMD 
to baseline levels before entering menopause. The relation 
between DMPA-associated changes in BMD during the re-
productive years and future fracture risk is unknown (1–41). 
Studies find no effect or have inconsistent results about the 
effects of POCs other than DMPA on BMD (42–54).
b. 18–45 yrs 1 1 1
c. >45 yrs 1 2 1
Parity
a. Nulliparous 1 1 1
b. Parous 1 1 1
Breastfeeding Clarification: The U.S. Department of Health and Human 
Services recommends that infants be exclusively breastfed 
during the first 4–6 months of life, preferably for a full 6 
months. Ideally, breastfeeding should continue through the 
first year of life (55).
Evidence: Despite anecdotal clinical reports that POCs 
might diminish milk production, direct evidence from avail-
able clinical studies demonstrates no significant negative 
effect of POCs on breastfeeding performance (56–90) or on 
the health of the infant (66,70,72,76–81,91–93). In general, 
these studies are of poor quality, lack standard definitions of 
breastfeeding or outcome measures, and have not included 
premature or ill infants. Theoretical concerns about effects 
of progestin exposure on the developing, neonatal brain 
are based on studies of progesterone effects in animals; 
whether similar effects occur after progestin exposure in 
human neonates is not known.
a. <1 mo postpartum 2 2 2
b. 1 mo to <6 mos postpartum 1 1 1
c. ≥6 mos postpartum 1 1 1
not protect against sexually transmitted infections (STIs) or 
human immunodeficiency virus (HIV).
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TABLE. (Continued) Classifications for progestin-only contraceptives,*† including progestin-only pills, DMPA, and implants
Condition
Category
Clarifications/Evidence/CommentsPOP DMPA Implants
Postpartum (in nonbreastfeeding 
women)
a. <21 days 1 1 1
b. ≥21 days 1 1 1
Postabortion Clarification: POCs may be started immediately 
postabortion.
Evidence: Limited evidence suggests that there are no 
adverse side effects when implants (Norplant) or progestin-
only injectables (NET-EN) are initiated after first trimester 
abortion (94–97).
a. First trimester 1 1 1
b. Second trimester 1 1 1
c. Immediate postseptic abortion 1 1 1
Past ectopic pregnancy 2 1 1 Comments: POP users have a higher absolute rate of 
ectopic pregnancy than do users of other POCs but still less 
than using no method.
History of pelvic surgery 1 1 1
Smoking
a. Age <35 yrs 1 1 1
b. Age ≥35 yrs
 i. <15 Cigarettes/day 1 1 1
 ii. ≥15 Cigarettes/day 1 1 1
Obesity
a. ≥30 kg/m2 BMI 1 1 1
b. Menarche to <18 yrs and 
≥30 kg/m2 BMI
1 2 1 Evidence: Obese adolescents who used DMPA were 
more likely than obese nonusers, obese COC users, and 
nonobese DMPA users to gain weight. These associations 
were not observed among adult women. One small study 
did not observe increases in weight gain among adolescent 
Norplant users by any category of baseline weight (98–105).
History of bariatric surgery§
a. Restrictive procedures: decrease 
storage capacity of the stomach 
(vertical banded gastroplasty, 
laparoscopic adjustable gastric 
band, laparoscopic sleeve 
gastrectomy)
1 1 1 Evidence: Limited evidence demonstrated no substantial 
decrease in effectiveness of oral contraceptives among 
women who underwent laparoscopic placement of an 
adjustable gastric band (106).
b. Malabsorptive procedures: 
decrease absorption of nutrients 
and calories by shortening the 
functional length of the small 
intestine (Roux-en-Y gastric 
bypass, biliopancreatic diversion)
3 1 1 Evidence: Limited evidence demonstrated no substantial 
decrease in effectiveness of oral contraceptives among 
women who underwent a biliopancreatic diversion (107); 
however, evidence from pharmacokinetic studies suggested 
conflicting results of oral contraceptive effectiveness among 
women who underwent a jejunoileal bypass (108,109).
Comment: Bariatric surgical procedures involving a mal-
absorptive component have the potential to decrease oral 
contraceptive effectiveness, perhaps further decreased by 
postoperative complications, such as long-term diarrhea 
and/or vomiting.
Cardiovascular Disease
Multiple risk factors for arterial 
cardiovascular disease (such as 
older age, smoking, diabetes, and 
hypertension)
2 3 2 Clarification: When multiple major risk factors exist, risk for 
cardiovascular disease might increase substantially. Some 
POCs might increase the risk for thrombosis, although this 
increase is substantially less than with COCs. The effects of 
DMPA might persist for some time after discontinuation.
Hypertension
For all categories of hypertension, classifications are based on the assumption that no other risk factors exist for cardiovascular disease. When multiple risk factors do exist, 
risk for cardiovascular disease might increase substantially. A single reading of blood pressure level is not sufficient to classify a woman as hypertensive.
a. Adequately controlled 
hypertension 
1 2 1 Clarification: Women adequately treated for hypertension 
are at lower risk for acute myocardial infarction and stroke 
than are untreated women. Although no data exist, POC us-
ers with adequately controlled and monitored hypertension 
should be at lower risk for acute myocardial infarction and 
stroke than are untreated hypertensive POC users.
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TABLE. (Continued) Classifications for progestin-only contraceptives,*† including progestin-only pills, DMPA, and implants
Condition
Category
Clarifications/Evidence/CommentsPOP DMPA Implants
b. Elevated blood pressure levels 
(properly taken measurements)
 i. Systolic 140–159 mm Hg or 
diastolic 90–99 mm Hg
1 2 1 Evidence: Limited evidence suggests that among women 
with hypertension, those who used POPs or progestin-only 
injectables had a small increased risk for cardiovascular 
events than did women who did not use these methods 
(110).
 ii. Systolic ≥160 mm Hg or 
diastolic ≥100 mm Hg§
2 3 2
c. Vascular disease 2 3 2 Comment: Concern exists about hypo-estrogenic effects 
and reduced HDL levels, particularly among users of DMPA. 
However, there is little concern about these effects with re-
gard to POPs. The effects of DMPA might persist for some 
time after discontinuation
History of high blood pressure dur-
ing pregnancy (where current blood 
pressure is measurable and normal)
1 1 1
Deep venous thrombosis (DVT)/ 
Pulmonary embolism (PE)
a. History of DVT/PE, not on antico-
agulant therapy
 i. Higher risk for recurrent DVT/
PE (≥1 risk factors)
	 •	 History	of	estrogen-associ-
ated DVT/PE
	 •	 Pregnancy-associated	
DVT/PE
	 •	 Idiopathic	DVT/PE
	 •	 Known	thrombophilia,	
including antiphospholipid 
syndrome
	 •	 Active	cancer	(metastatic,	
on therapy, or within 6 mos 
after clinical remission), 
excluding non-melanoma 
skin cancer
	 •	 History	of	recurrent	DVT/PE
2 2 2
 ii Lower risk for recurrent DVT/
PE (no risk factors)
2 2 2
b. Acute DVT/PE 2 2 2 Evidence: No direct evidence exists on use of POCs 
among women with acute DVT/PE. Although findings on the 
risk for venous thrombosis with use of POCs in otherwise 
healthy women is inconsistent, any small increased risk is 
substantially less than that with COCs (110–112).
c. DVT/PE and established on 
anticoagulant therapy for at least 
3 mos
Evidence: No direct evidence exists on use of POCs 
among women with DVT/PE on anticoagulant therapy. 
Although findings on the risk for venous thrombosis with 
use of POCs are inconsistent in otherwise healthy women, 
any small increased risk is substantially less than that with 
COCs (110–112).
Limited evidence indicates that intramuscular injections of 
DMPA in women on chronic anticoagulation therapy does 
not pose a significant risk for hematoma at the injection site 
or increase the risk for heavy or irregular vaginal bleeding 
(113).
 i. Higher risk for recurrent DVT/
PE (≥1 risk factors)
	 •	 Known	thrombophilia,	
including antiphospholipid 
syndrome
	 •	 Active	cancer	(metastatic,	
on therapy, or within 6 mos 
after clinical remission), 
excluding non-melanoma 
skin cancer
	 •	 History	of	recurrent	DVT/PE
2 2 2
 ii. Lower risk for recurrent DVT/
PE (no risk factors)
2 2 2
d. Family history 
(first-degree relatives)
1 1 1
e. Major surgery
 i. With prolonged immobilization 2 2 2
 ii. Without prolonged 
immobilization
1 1 1
f. Minor surgery without 
immobilization
1 1 1
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TABLE. (Continued) Classifications for progestin-only contraceptives,*† including progestin-only pills, DMPA, and implants
Condition
Category
Clarifications/Evidence/CommentsPOP DMPA Implants
Known thrombogenic mutations§ 
(e.g., factor V Leiden; prothrombin 
mutation; protein S, protein C, and 
antithrombin deficiencies)
2 2 2 Clarification: Routine screening is not appropriate because 
of the rarity of the conditions and the high cost of screening.
Superficial venous thrombosis
a. Varicose veins 1 1 1
b. Superficial thrombophlebitis 1 1 1  
Current and history of ischemic 
heart disease§ 
Initiation Continuation Initiation Continuation Comment: Concern exists about hypo-estrogenic effects 
and reduced HDL levels, particularly among users of DMPA. 
However, there is little concern about these effects with re-
gard to POPs. The effects of DMPA might persist for some 
time after discontinuation.
2 3 3 2 3
Stroke§ (history of cerebrovascular 
accident)
Initiation Continuation Initiation Continuation Comment: Concern exists about hypo-estrogenic effects 
and reduced HDL levels, particularly among users of DMPA. 
However, there is little concern about these effects with 
regard to POPs. The effects of DMPA may persist for some 
time after discontinuation.
2 3 3 2 3
Known hyperlipidemias 2 2 2 Clarification: Routine screening is not appropriate because 
of the rarity of the conditions and the high cost of screening. 
Some types of hyperlipidemias are risk factors for vascular 
disease.
Valvular heart disease
a. Uncomplicated 1 1 1
b. Complicated§ (pulmonary hyper-
tension, risk for atrial fibrillation, 
history of subacute bacterial 
endocarditis)
1 1 1
Peripartum cardiomyopathy§
a. Normal or mildly impaired 
cardiac function (New York Heart 
Association Functional Class I or 
II: patients with no limitation of ac-
tivities or patients with slight, mild 
limitation of activity) (114)
Evidence: No direct evidence exists on the safety of POCs 
among women with peripartum cardiomyopathy. Limited in-
direct evidence from noncomparative studies of women with 
cardiac disease demonstrated few cases of hypertension, 
thromoboembolism, and heart failure in women with cardiac 
disease using POPs and DMPA (115,116).
Comment: Progestin-only implants might induce cardiac 
arrhythmias in healthy women; women with peripartum car-
diomyopathy have a high incidence of cardiac arrhythmias.
 i. <6 mos 1 1 1
 ii. ≥6 mos 1 1 1
b. Moderately or severely impaired 
cardiac function (New York Heart 
Association Functional Class III or 
IV: patients with marked limitation 
of activity or patients who should 
be at complete rest) (114)
2 2 2 Evidence: No direct evidence exists on the safety of POCs 
among women with peripartum cardiomyopathy. Limited in-
direct evidence from noncomparative studies of women with 
cardiac disease demonstrated few cases of hypertension, 
thromoboembolism, and heart failure in women with cardiac 
disease using POPs and DMPA (115,116).
Comment: Progestin-only implants might induce cardiac 
arrhythmias in healthy women; women with peripartum car-
diomyopathy have a high incidence of cardiac arrhythmias.
38 Early Release May 28, 2010
TABLE. (Continued) Classifications for progestin-only contraceptives,*† including progestin-only pills, DMPA, and implants
Condition
Category
Clarifications/Evidence/CommentsPOP DMPA Implants
Rheumatic Diseases
Systemic lupus erythematosus (SLE)§
Persons with SLE are at increased risk for ischemic heart disease, stroke, and VTE. Categories assigned to such conditions in the MEC should be the same for women with 
SLE who present with these conditions. For all categories of SLE, classifications are based on the assumption that no other risk factors for cardiovascular disease are present; 
these classifications must be modified in the presence of such risk factors.
Many women with SLE can be considered good candidates for most contraceptive methods, including hormonal contraceptives (117–135).
a. Positive (or unknown) antiphos-
pholipid antibodies
Initiation Continuation Evidence: Antiphospholipid antibodies are associated 
with a higher risk for both arterial and venous thrombosis 
(136,137).
3 3 3 3
b. Severe thrombocytopenia 2 3 2 2 Comment: Severe thrombocytopenia increases the risk for 
bleeding. POCs might be useful in treating menorrhagia in 
women with severe thrombocytopenia. However, given the 
increased or erratic bleeding that may be seen on initiation 
of DMPA and its irreversibility for 11–13 weeks after ad-
ministration, initiation of this method in women with severe 
thrombocytopenia should be done with caution.
c. Immunosuppressive treatment 2 2 2 2
d. None of the above 2 2 2 2
Rheumatoid arthritis
a. On immunosuppressive therapy 1 2/3 1 Clarification: DMPA use among women on long-term 
corticosteroid therapy with a history of, or with risk factors 
for, nontraumatic fractures is classified as Category 3. 
Otherwise, DMPA use for women with rheumatoid arthritis is 
classified as Category 2.
Evidence: Limited evidence shows no consistent pattern of 
improvement or worsening of rheumatoid arthritis with use 
of oral contraceptives (138–143), progesterone (144), or 
estrogen (145).
b. Not on immunosuppressive 
therapy
1 2 1
Neurologic Conditions
Headaches Initiation Continuation Initiation Continuation Initiation Continuation Clarification: Classification depends on accurate diagnosis 
of severe headaches that are migrainous and headaches 
that are not. Any new headaches or marked changes in 
headaches should be evaluated. Classification is for women 
without any other risk factors for stroke. Risk for stroke 
increases with age, hypertension, and smoking.
Comment: Aura is a specific focal neurologic symptom. 
For more information about this and other diagnostic 
criteria, see: Headache Classification Subcommittee of the 
International Headache Society. The international classifica-
tion of headache disorders. 2nd Ed. Cephalalgia. 2004;24 
(Suppl 1):1–150. http://www.i-h-s.org/upload/ct_clas/ihc_II_
main_no_print.pdf.
Concern exists that severe headaches might increase 
with use of DMPA and implants. The effects of DMPA may 
persist for some time after discontinuation. 
a. Non-migrainous 
(mild or severe)
1 1 1 1 1 1
b. Migraine
 i. Without aura
•	Age <35 yrs 1 2 2 2 2 2
•	Age ≥35 yrs 1 2 2 2 2 2
 ii. With aura, at any age 2 3 2 3 2 3
Epilepsy§ 1 1 1 Clarification: If a woman is taking anticonvulsants, refer 
to the section on drug interactions. Certain anticonvulsants 
lower POC effectiveness. 
Depressive Disorders
Depressive disorders 1 1 1 Clarification: The classification is based on data for women 
with selected depressive disorders. No data on bipolar dis-
order or postpartum depression were available. A potential 
exists for drug interactions between certain antidepressant 
medications and hormonal contraceptives. 
Evidence: POC use did not increase depressive symp-
toms in women with depression compared with baseline 
(146–149).
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TABLE. (Continued) Classifications for progestin-only contraceptives,*† including progestin-only pills, DMPA, and implants
Condition
Category
Clarifications/Evidence/CommentsPOP DMPA Implants
Reproductive Tract Infections and Disorders
Vaginal bleeding patterns
a. Irregular pattern without heavy 
bleeding
2 2 2 Comment: Irregular menstrual bleeding patterns are com-
mon among healthy women. POC use frequently induces an 
irregular bleeding pattern. Implant use might induce irregular 
bleeding patterns, especially during the first 3–6 months, but 
these patterns may persist longer.
b. Heavy or prolonged bleeding 
(includes regular and irregular 
patterns)
2 2 2 Clarification: Unusually heavy bleeding should raise the 
suspicion of a serious underlying condition.
Unexplained vaginal bleeding 
(suspicious for serious condition)
Clarification: If pregnancy or an underlying pathological 
condition (such as pelvic malignancy) is suspected, it must 
be evaluated and the category adjusted after evaluation.
Comment: POCs might cause irregular bleeding patterns, 
which might mask symptoms of underlying pathology. 
The effects of DMPA might persist for some time after 
discontinuation.
Before evaluation 2 3 3
Endometriosis 1 1 1
Benign ovarian tumors 
(including cysts)
1 1 1
Severe dysmenorrhea 1 1 1
Gestational trophoblastic disease
a. Decreasing or undetectable 
β–hCG levels
1 1 1
b. Persistently elevated β-hCG 
levels or malignant disease§
1 1 1
Cervical ectropion 1 1 1
Cervical intraepithelial neoplasia 1 2 2 Evidence: Among women with persistent HPV infection, 
long-term DMPA use (≥5 years) might increase the risk for 
carcinoma in situ and invasive carcinoma (150).
Cervical cancer (awaiting treatment) 1 2 2 Comment: Theoretical concern exists that POC use might 
affect prognosis of the existing disease. While awaiting 
treatment, women may use POCs. In general, treatment of 
this condition can render a woman sterile.
Breast disease
a. Undiagnosed mass 2 2 2 Clarification: Evaluation should be pursued as early as 
possible.
b. Benign breast disease 1 1 1
c. Family history of cancer 1 1 1
d. Breast cancer§
 i. Current 4 4 4 Comment: Breast cancer is a hormonally sensitive tumor, 
and the prognosis for women with current or recent breast 
cancer might worsen with POC use.
 ii. Past and no evidence of 
current disease for 5 years
3 3 3
Endometrial hyperplasia 1 1 1
Endometrial cancer§ 1 1 1 Comment: While awaiting treatment, women may use 
POCs. In general, treatment of this condition renders a 
woman sterile.
Ovarian cancer§ 1 1 1 Comment: While awaiting treatment, women may use 
POCs. In general, treatment of this condition can render a 
woman sterile.
Uterine fibroids 1 1 1 Comment: POCs do not appear to cause growth of uterine 
fibroids.
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TABLE. (Continued) Classifications for progestin-only contraceptives,*† including progestin-only pills, DMPA, and implants
Condition
Category
Clarifications/Evidence/CommentsPOP DMPA Implants
Pelvic inflammatory disease (PID)
a. Past PID (assuming no current 
risk factors for STIs)
Comment: Whether POCs, like COCs, reduce the risk for 
PID among women with STIs is unknown, but they do not 
protect against HIV or lower genital tract STI.
  i. With subsequent pregnancy 1 1 1
  ii. Without subsequent 
pregnancy
1 1 1
b. Current PID 1 1 1
STIs
a. Current purulent cervicitis or 
chlamydial infection or gonorrhea
1 1 1
b. Other STIs (excluding HIV and 
hepatitis)
1 1 1
c. Vaginitis (including Trichomonas 
vaginalis and bacterial vaginosis)
1 1 1
d. Increased risk for STIs 1 1 1 Evidence: Evidence suggests a possible increased risk 
for chlamydial cervicitis among DMPA users at high risk for 
STIs. For other STIs, either evidence exists of no associa-
tion between DMPA use and STI acquisition or evidence is 
too limited to draw any conclusions. No evidence is avail-
able about other POCs (151–158)
HIV/AIDS
High risk for HIV 1 1 1 Evidence: The balance of the evidence suggests no as-
sociation between POC use and HIV acquisition, although 
findings from studies of DMPA use conducted among higher 
risk populations have been inconsistent (159–183).
HIV infection§ 1 1 1 Evidence: Most studies suggest no increased risk for HIV 
disease progression with hormonal contraceptive use, 
as measured by changes in CD4 cell count, viral load, or 
survival. Studies observing that women with HIV who use 
hormonal contraception have increased risks for STIs are 
generally consistent with reports among uninfected women. 
One direct study found no association between hormonal 
contraceptive use and increased risk for HIV transmission to 
uninfected partners; several indirect studies reported mixed 
results about whether hormonal contraception is associated 
with increased risk for HIV-1 DNA or RNA shedding from the 
genital tract (171,184–200).
AIDS§ 1 1 1 Clarification: Drug interactions might exist between 
hormonal contraceptives and ARV drugs; refer to the 
section on drug interactions.
Other Infections
Schistosomiasis
a. Uncomplicated 1 1 1 Evidence: Among women with uncomplicated schistoso-
miasis, limited evidence showed that DMPA use had no 
adverse effects on liver function (201).
b. Fibrosis of liver§ 
(if severe, see cirrhosis)
1 1 1
Tuberculosis§ Clarification: If a woman is taking rifampicin, refer to the 
section on drug interactions. Rifampicin is likely to decrease 
the effectiveness of some POCs.
a. Nonpelvic 1 1 1
b. Pelvic 1 1 1
Malaria 1 1 1
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Condition
Category
Clarifications/Evidence/CommentsPOP DMPA Implants
Endocrine Conditions
Diabetes
a. History of gestational disease 1 1 1 Evidence: POCs had no adverse effects on serum lipid 
levels in women with a history of gestational diabetes in 2 
small studies. (202,203) Limited evidence is inconsistent 
about the development of noninsulin-dependant diabetes 
among users of POCs with a history of gestational diabetes 
(204–207).
b. Nonvascular disease
 i. Noninsulin-dependent 2 2 2 Evidence: Among women with insulin- or noninsulin-de-
pendent diabetes, limited evidence on use of POCs (POPs, 
DMPA, LNG implant) suggests that these methods have 
little effect on short-term or long-term diabetes control (e.g., 
glycosylated hemoglobin levels), hemostatic markers, or 
lipid profile (208–211).
 ii. Insulin-dependent§ 2 2 2
c. Nephropathy/retinopathy/ 
neuropathy§
2 3 2 Comment: Concern exists about hypo-estrogenic effects 
and reduced HDL levels, particularly among users of DMPA. 
The effects of DMPA might persist for some time after 
discontinuation. Some POCs might increase the risk for 
thrombosis, although this increase is substantially less than 
with COCs.
d. Other vascular disease or 
diabetes of >20 yrs’ duration§
2 3 2 Comment: Concern exists about hypo-estrogenic effects 
and reduced HDL levels, particularly among users of DMPA. 
The effects of DMPA might persist for some time after 
discontinuation. Some POCs might increase the risk for 
thrombosis, although this increase is substantially less than 
with COCs.
Thyroid disorders
a. Simple goiter 1 1 1
b. Hyperthyroid 1 1 1
c. Hypothyroid 1 1 1
Gastrointestinal Conditions
Inflammatory bowel disease (IBD) 
(ulcerative colitis, Crohn disease)
2 2 1 Evidence: Risk for disease relapse among women with 
IBD using oral contraceptives (most studies did not specify 
formulation) did not increase significantly from that for 
nonusers (212–216).
Comment: Absorption of POPs among women with IBD 
might be reduced if the woman has substantial malabsorp-
tion caused by severe disease or small bowel surgery. 
Women with IBD have a higher prevalence than the general 
population of osteoporosis and osteopenia. Use of DMPA, 
which has been associated with small changes in BMD, 
might be of concern.
Gallbladder disease
a. Symptomatic
 i. Treated by cholecystectomy 2 2 2
 ii. Medically treated 2 2 2
 iii. Current 2 2 2
b. Asymptomatic 2 2 2
History of cholestasis
a. Pregnancy-related 1 1 1
b. Past COC–related 2 2 2 Comment: Theoretically, a history of COC-related cholesta-
sis might predict subsequent cholestasis with POC use. 
However, this has not been documented.
Viral hepatitis
a. Acute or flare 1 1 1
b. Carrier 1 1 1
c. Chronic 1 1 1
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Condition
Category
Clarifications/Evidence/CommentsPOP DMPA Implants
Cirrhosis
a. Mild (compensated) 1 1 1
b. Severe§ (decompensated) 3 3 3
Liver tumors
a. Benign Evidence: Limited direct evidence suggests that hormonal 
contraceptive use does not influence either progression or 
regression of liver lesions among women with focal nodular 
hyperplasia (217,218).
Comment: No evidence is available about hormonal con-
traceptive use among women with hepatocellular adenoma. 
COC use in healthy women is associated with development 
and growth of hepatocellular adenoma; whether other hor-
monal contraceptives have similar effects is not known.
 i. Focal nodular hyperplasia 2 2 2
 ii. Hepatocellular adenoma§ 3 3 3
b. Malignant§ (hepatoma) 3 3 3
Anemias
Thalassemia 1 1 1
Sickle cell disease§ 1 1 1 Evidence: Among women with sickle cell disease, POC use 
did not have adverse effects on hematologic parameters 
and, in some studies, was beneficial with respect to clinical 
symptoms (219–226).
Iron deficiency anemia 1 1 1 Comment: Changes in the menstrual pattern associated 
with POC use have little effect on hemoglobin levels.
Solid Organ Transplantation
Solid organ transplantaton§
a. Complicated: graft failure (acute 
or chronic), rejection, cardiac 
allograft vasculopathy
2 2 2
b. Uncomplicated 2 2 2
Drug Interactions
Antiretroviral (ARV) therapy Clarification: ARV drugs have the potential to either 
decrease or increase the bioavailability of steroid hormones 
in hormonal contraceptives. Limited data (Appendix M) sug-
gest potential drug interactions between many ARV drugs 
(particularly some NNRTIs and ritonavir-boosted protease 
inhibitors) and hormonal contraceptives. These interactions 
may alter the safety and effectiveness of both the hormonal 
contraceptive and the ARV drug. Thus, if a woman on ARV 
treatment decides to initiate or continue hormonal contra-
ceptive use, the consistent use of condoms is recommend-
ed to both prevent HIV transmission and compensate for 
any possible reduction in the effectiveness of the hormonal 
contraceptive.
a. Nucleoside reverse transcriptase 
inhibitors (NRTIs)
1 1 1
b. Non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs)
2 1 2
c. Ritonavir-boosted protease 
inhibitors
3 1 2
Anticonvulsant therapy
a. Certain anticonvulsants (pheny-
toin, carbamazepine, barbitu-
rates, primidone, topiramate, 
oxcarbazepine)
3 1 2 Clarification: Although the interaction of certain anticon-
vulsants with POPs and ETG implants is not harmful to 
women, it is likely to reduce the effectiveness of POPs and 
ETG implants. Whether increasing the hormone dose of 
POPs alleviates this concern remains unclear. Use of other 
contraceptives should be encouraged for women who are 
long-term users of any of these drugs. Use of DMPA is a 
Category 1 because its effectiveness is not decreased by 
use of certain anticonvulsants.
Evidence: Use of certain anticonvulsants may decrease the 
effectiveness of POCs (227–229)
b. Lamotrigine 1 1 1 Evidence: No drug interactions have been reported among 
epileptic women taking lamotrigine and using POCs (230)
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Condition
Category
Clarifications/Evidence/CommentsPOP DMPA Implants
Antimicrobial therapy
a. Broad-spectrum antibiotics 1 1 1
b. Antifungals 1 1 1
c. Antiparasitics 1 1 1
d. Rifampicin or rifabutin therapy 3 1 2 Clarification: Although the interaction of rifampicin or rifab-
utin with POPs and ETG implants is not harmful to women, 
it is likely to reduce the effectiveness of POPs and ETG 
implants. Use of other contraceptives should be encouraged 
for women who are long-term users of any of these drugs. 
Use of DMPA is a Category 1 because its effectiveness is 
not decreased by use of rifampicin or rifabutin. Whether in-
creasing the hormone dose of POPs alleviates this concern 
remains unclear.
* Abbreviations: STI = sexually transmitted infection; HIV = human immunodeficiency virus; POC = progestin-only contraceptive; DMPA = depot medroxyprogesterone acetate; 
BMD = bone mineral density; NET-EN = norethisterone enantate; BMI = body mass index; COC = combined oral contraceptive; HDL = high-density lipoprotein; POP = progestin-
only pill; DVT = deep venous thrombosis; PE = pulmonary embolism; SLE = systemic lupus erythematosus; VTE = venous thromboembolism; MEC = Medical Eligibility Criteria; 
hCG = human chorionic gonadotropin; HPV = human papillomavirus; PID = pelvic inflammatory disease; AIDS = acquired immunodeficiency syndrome; IBD = inflammatory 
bowel disease; ARV = antiretroviral; LNG = levonorgestrel; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; ETG = 
etonogestrel.
† POCs do not protect against STI/HIV. If risk exists for STI/HIV (including during pregnancy or postpartum), the correct and consistent use of condoms is recommended, either 
alone or with another contraceptive method. Consistent and correct use of the male latex condom reduces the risk for STIs and HIV transmission.
§ Condition that exposes a woman to increased risk as a result of unintended pregnancy.
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Appendix D 
Classifications for Emergency Contraceptive Pills
BOX. Categories for Classifying Emergency Contraceptive Pills
1 = A condition for which there is no restriction for the use of the contraceptive method.
2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.
3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.
4 = A condition that represents an unacceptable health risk if the contraceptive method is used.
TABLE. Classifications for emergency contraceptive pills, including levonorgestrel contraceptive pills and combined oral 
contraceptive pills*†
Condition Category Clarifications/Evidence/Comments
Personal Characteristics and Reproductive History
Pregnancy Not applicable Clarification: Although this method is not indicated for a woman with a known or 
suspected pregnancy, no harm to the woman, the course of her pregnancy, or the 
fetus if ECPs are inadvertently used is known to exist. 
Breastfeeding
1
Past ectopic pregnancy
1
History of bariatric surgery§
a. Restrictive procedures: decrease storage capacity of the stom-
ach (vertical banded gastroplasty, laparoscopic adjustable 
gastric band, laparoscopic sleeve gastrectomy)
1
b. Malabsorptive procedures: decrease absorption of nutrients 
and calories by shortening the functional length of the small 
intestine (Roux-en-Y gastric bypass, biliopancreatic diversion)
1 Comment: Bariatric surgical procedures involving a malabsorptive component 
have the potential to decrease oral contraceptive effectiveness, perhaps further 
decreased by postoperative complications such as long-term diarrhea and/or 
vomiting. Because of these malabsorptive concerns, an emergency IUD might be 
more appropriate than ECPs.
Cardiovascular Disease
History of severe cardiovascular complications§ (ischemic 
heart disease, cerebrovascular attack, or other thromboembolic 
conditions)
2 Comment: The duration of ECP use is less than that of regular use of COCs or 
POPs and thus would be expected to have less clinical impact.
Angina pectoris 2 Comment: The duration of ECP use is less than that of regular use of COCs or 
POPs and thus would be expected to have less clinical impact.
Rheumatic Diseases
Rheumatoid arthritis
a. On immunosuppressive therapy 1
b. Not on immunosuppressive therapy 1
Neurologic Conditions
Migraine 2 Comment: The duration of ECP use is less than that of regular use of COCs or 
POPs and thus would be expected to have less clinical impact.
Gastrointestinal Conditions
Inflammatory bowel disease (ulcerative colitis, Crohn disease) 1
Severe liver disease§ (including jaundice) 2 Comment: The duration of ECP use is less than that of regular use of COCs or 
POPs and thus would be expected to have less clinical impact.
Solid Organ Transplantation
Solid organ transplantation§
a. Complicated: graft failure (acute or chronic), rejection, 
cardiac allograft vasculopathy
1
b. Uncomplicated 1
Classifications for emergency contraceptive pills (ECPs) are 
for both levonorgestrel and combined oral contraceptive pills. 
ECPs do not protect against sexually transmitted infections 
(STIs) or human immunodeficiency virus (HIV).
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TABLE. (Continued) Classifications for emergency contraceptive pills, including levonorgestrel contraceptive pills and combined 
oral contraceptive pills*†
Condition Category Clarifications/Evidence/Comments
Other
Repeated ECP use 1 Clarification: Recurrent ECP use is an indication that the woman requires further 
counseling about other contraceptive options. Frequently repeated ECP use may 
be harmful for women with conditions classified as 2, 3, or 4 for CHC or POC use. 
Rape 1 Comment: Use of ECPs in cases of rape has no restrictions.
* Abbreviations: STI = sexually transmitted infection; HIV = human immunodeficiency virus; ECP, emergency contraceptive pill; IUD = intrauterine device; COC = combined oral 
contraceptive; POP = progestin-only pill; CHC = combined hormonal contraceptive; POC = progestin-only contraceptive 
† ECPs do not protect against STI/HIV. If risk exists for STI/HIV (including during pregnancy or postpartum), the correct and consistent use of condoms is recommended, either 
alone or with another contraceptive method. Consistent and correct use of the male latex condom reduces the risk for STIs and HIV transmission.
§ Condition that exposes a woman to increased risk as a result of unintended pregnancy.
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Appendix E
 Classifications for Intrauterine Devices
Classifications for intrauterine devices (IUDs) are for the 
levonorgestrel-releasing (20 μg/24 hours) IUD and the copper-
bearing IUD (Box). IUDs do not protect against sexually 
BOX. Categories for Classifying Intrauterine Devices
1 = A condition for which there is no restriction for the use of the contraceptive method.
2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.
3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.
4 = A condition that represents an unacceptable health risk if the contraceptive method is used.
TABLE. Classifications for intrauterine devices, including the LNG-IUD and the Cu-IUD*†
Condition
Category
Clarifications/Evidence/CommentsLNG-IUD Cu-IUD
Personal Characteristics and Reproductive History
Pregnancy 4 4 Clarification: The IUD is not indicated during pregnancy and 
should not be used because of the risk for serious pelvic infection 
and septic spontaneous abortion.
Age
a. Menarche to <20 yrs 2 2 Comment: Concern exists about both the risk for expulsion from 
nulliparity and for STIs from sexual behaviour in younger age 
groups.
b. ≥20 yrs 1 1
Parity
a. Nulliparous 2 2 Evidence: Data conflict about whether IUD use is associated 
with infertility among nulliparous women, although well-conducted 
studies suggest no increased risk (1–9).
b Parous 1 1
Postpartum (breastfeeding or nonbreast-
feeding women, including post-Cesarean 
section)
a. <10 minutes after delivery of the 
placenta
2 1 Evidence: Immediate postpartum Cu-IUD insertion, particularly 
when insertion occurs immediately after delivery of the placenta, is 
associated with lower expulsion rates than is delayed postpartum 
insertion up to 72 hours postpartum; no data exist that examine 
times >72 hours postpartum. In addition, postplacental placement 
at the time of Cesarean section has lower expulsion rates than 
does postplacental vaginal insertions. Insertion complications of 
perforation and infection are not increased by Cu-IUD placement 
at any time during the postpartum period (10–23). No evidence is 
available that compares different insertion times for the LNG-IUD.
b. 10 minutes after delivery of the 
placenta to <4 wks
2 2
c. ≥4 wks 1 1
d. Puerperal sepsis 4 4 Comment: Insertion of an IUD might substantially worsen the 
condition.
Postabortion
a. First trimester 1 1 Clarification: IUDs can be inserted immediately after first trimes-
ter spontaneous or induced abortion.
Evidence: Risk for complications from immediate versus delayed 
insertion of an IUD after abortion did not differ. Expulsion was 
greater when an IUD was inserted after a second trimester abor-
tion than when inserted after a first trimester abortion. Safety or 
expulsion for postabortion insertion of an LNG-IUD did not differ 
from that of a Cu-IUD (24–37).
b. Second trimester 2 2
c. Immediate postseptic abortion 4 4 Comment: Insertion of an IUD might substantially worsen the 
condition.
transmitted infections (STIs) or human immunodeficiency 
virus (HIV).
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TABLE. (Continued) Classifications for intrauterine devices,*† including the LNG-IUD and the Cu-IUD
Condition
Category
Clarifications/Evidence/CommentsLNG-IUD Cu-IUD
Past ectopic pregnancy 1 1 Comment: The absolute risk for ectopic pregnancy is extremely 
low because of the high effectiveness of IUDs. However, when a 
woman becomes pregnant during IUD use, the relative likelihood 
of ectopic pregnancy increases greatly.
History of pelvic surgery (see Postpartum, 
including post-Cesarean section)
1 1
Smoking
a. Age <35 yrs 1 1
b. Age ≥35 yrs
 i. <15 Cigarettes/day 1 1
 ii. ≥15 Cigarettes/day 1 1
Obesity
a. ≥30 kg/m2 BMI 1 1
b. Menarche to <18 yrs and ≥30 kg/m2 BMI 1 1
History of bariatric surgery§
a. Restrictive procedures: decrease stor-
age capacity of the stomach (vertical 
banded gastroplasty, laparoscopic 
adjustable gastric band, laparoscopic 
sleeve gastrectomy)
1 1
b. Malabsorptive procedures: decrease 
absorption of nutrients and calories 
by shortening the functional length of 
the small intestine (Roux-en-Y gastric 
bypass, biliopancreatic diversion)
1 1
Cardiovascular Disease
Multiple risk factors for arterial cardio-
vascular disease (such as older age, 
smoking, diabetes, and hypertension)
2 1
Hypertension
For all categories of hypertension, classifications are based on the assumption that no other risk factors for cardiovascular disease exist. When multiple risk factors do exist, 
risk for cardiovascular disease might increase substantially. A single reading of blood pressure level is not sufficient to classify a woman as hypertensive.
a. Adequately controlled hypertension 1 1
b. Elevated blood pressure levels (properly 
taken measurements)
 i. Systolic 140–159 mm Hg or diastolic 
90–99 mm Hg
1 1
 ii. Systolic ≥160 mm Hg or diastolic 
≥100 mm Hg§
2 1 Comment: Theoretical concern exists about the effect of LNG on 
lipids. Use of Cu-IUDs has no restrictions.
c. Vascular disease 2 1 Comment: Theoretical concern exists about the effect of LNG on 
lipids. Use of Cu-IUDs has no restrictions.
History of high blood pressure during 
pregnancy (where current blood pressure is 
measurable and normal)
1 1
Deep venous thrombosis (DVT)/
pulmonary embolism (PE)
a. History of DVT/PE, not on anticoagulant 
therapy
 i. Higher risk for recurrent DVT/PE (≥1 
risk factors)
	 •	 History	of	estrogen-associated	
DVT/PE
	 •	 Pregnancy-associated	DVT/PE
	 •	 Idiopathic	DVT/PE
	 •	 Known	thrombophilia,	including	
antiphospholipid syndrome
	 •	 Active	cancer	(metastatic,	on	
therapy, or within 6 mos after 
clinical remission), excluding non-
melanoma skin cancer
	 •	 History	of	recurrent	DVT/PE
2 1
 ii. Lower risk for recurrent DVT/PE (no 
risk factors)
2 1
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TABLE. (Continued) Classifications for intrauterine devices,*† including the LNG-IUD and the Cu-IUD
Condition
Category
Clarifications/Evidence/CommentsLNG-IUD Cu-IUD
b. Acute DVT/PE 2 2 Evidence: No direct evidence exists on the use of POCs among 
women with acute DVT/PE. Although findings on the risk for 
venous thrombosis with the use of POCs in otherwise healthy 
women are inconsistent, any small increased risk is substantially 
less than that with COCs (38–40).
c. DVT/PE and established on anticoagu-
lant therapy for at least 3 mos
Evidence: No direct evidence exists on the use of POCs among 
women with acute DVT/PE. Although findings on the risk for 
venous thrombosis with the use of POCs in otherwise healthy 
women are inconsistent, any small increased risk is substantially 
less than that with COCs (38–40).
Evidence: Limited evidence indicates that insertion of the LNG-
IUD does not pose major bleeding risks in women on chronic 
anticoagulant therapy. (41–44)
Comment: The LNG-IUD might be a useful treatment for menor-
rhagia in women on long-term chronic anticoagulation therapy.
 i. Higher risk for recurrent DVT/PE (≥1 
risk factors)
	 •	 Known	thrombophilia,	including	
antiphospholipid syndrome
	 •	 Active	cancer	(metastatic,	on	
therapy, or within 6 mos after 
clinical remission), excluding non-
melanoma skin cancer
	 •	 History	of	recurrent	DVT/PE
2 2
 ii. Lower risk for recurrent DVT/PE (no 
risk factors)
2 2
d. Family history (first-degree relatives) 1 1
e. Major surgery
 i. With prolonged immobilization 2 1
 ii. Without prolonged immobilization 1 1
f. Minor surgery without immobilization 1 1
Known thrombogenic mutations§ (e.g., 
factor V Leiden; prothrombin mutation; 
protein S, protein C, and antithrombin 
deficiencies)
2 1 Clarification: Routine screening is not appropriate because of the 
rarity of the conditions and the high cost of screening.
Superficial venous thrombosis
a. Varicose veins 1 1
b. Superficial thrombophlebitis 1 1
Current and history of ischemic heart 
disease§
Initiation Continuation Comment: Theoretical concern exists about the effect of LNG on 
lipids. Use of Cu-IUDs has no restrictions.
2 3 1
Stroke§ (history of cerebrovascular 
accident)
2 1 Comment: Theoretical concern exists about the effect of LNG on 
lipids. Use of Cu-IUDs has no restrictions.
Known hyperlipidemias 2 1 Clarification: Routine screening is not appropriate because of the 
rarity of the condition and the high cost of screening. 
Valvular heart disease
a. Uncomplicated 1 1 Comment: According to the American Heart Association, admin-
istration of prophylactic antibiotics solely to prevent endocarditis 
is not recommended for patients who undergo genitourinary tract 
procedures, including insertion or removal of IUDs (45).
b. Complicated§ (pulmonary hyperten-
sion, risk for atrial fibrillation, history of 
subacute bacterial endocarditis)
1 1 Comment: According to the American Heart Association, admin-
istration of prophylactic antibiotics solely to prevent endocarditis 
is not recommended for patients who undergo genitourinary tract 
procedures, including insertion or removal of IUDs (45).
Peripartum cardiomyopathy§
a. Normal or mildly impaired cardiac 
function (New York Heart Association 
Functional Class I or II: patients with no 
limitation of activities or patients with 
slight, mild limitation of activity) (46)
Evidence: No direct evidence exists on the safety of IUDs among 
women with peripartum cardiomyopathy. Limited indirect evidence 
from noncomparative studies did not demonstrate any cases of 
arrhythmia or infective endocarditis in women with cardiac disease 
who used IUDs (47,48).
Comment: IUD insertion might induce cardiac arrhythmias in 
healthy women; women with peripartum cardiomyopathy have a 
high incidence of cardiac arrhythmias.
 i. <6 mos 2 2
 ii. ≥6 mos 2 2
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TABLE. (Continued) Classifications for intrauterine devices,*† including the LNG-IUD and the Cu-IUD
Condition
Category
Clarifications/Evidence/CommentsLNG-IUD Cu-IUD
b. Moderately or severely impaired cardiac 
function (New York Heart Association 
Functional Class III or IV: patients with 
marked limitation of activity or patients 
who should be at complete rest) (46)
2 2 Evidence: There is no direct evidence on the safety of IUDs 
among women with peripartum cardiomyopathy. Limited indirect 
evidence from noncomparative studies did not demonstrate any 
cases of arrhythmia or infective endocarditis in women with car-
diac disease who used IUDs (47,48).
Comment: IUD insertion might induce cardiac arrhythmias in 
healthy women; women with peripartum cardiomyopathy have a 
high incidence of cardiac arrhythmias.
Rheumatic Diseases
Systemic lupus erythematosus (SLE)§
Persons with SLE are at increased risk for ischemic heart disease, stroke, and VTE. Categories assigned to such conditions in the MEC should be the same for women 
with SLE who have these conditions. For all categories of SLE, classifications are based on the assumption that no other risk factors for cardiovascular disease are present; 
these classifications must be modified in the presence of such risk factors.
Many women with SLE can be considered good candidates for most contraceptive methods, including hormonal contraceptives (43,49–66).
Initiation Continuation
a. Positive (or unknown) antiphospholipid 
antibodies
3 1 1 Evidence: Antiphospholipid antibodies are associated with a 
higher risk for both arterial and venous thrombosis (67,68).
b. Severe thrombocytopenia 2 3 2 Clarification: Severe thrombocytopenia increases the risk for 
bleeding. The category should be assessed according to the 
severity of thrombocytopenia and its clinical manifestations. In 
women with very severe thrombocytopenia who are at risk for 
spontaneous bleeding, consultation with a specialist and certain 
pretreatments might be warranted.
Evidence: The LNG-IUD might be a useful treatment for menor-
rhagia in women with severe thrombocytopenia (43).
c. Immunosuppressive treatment 2 2 1
d. None of the above 2 1 1
Rheumatoid arthritis Initiation Continuation Initiation Continuation
a. On immunosuppressive therapy 2 1 2 1
b. Not on immunosuppressive therapy 1 1
Neurologic Conditions
Headaches Initiation Continuation Clarification: Any new headaches or marked changes in head-
aches should be evaluated.
a. Non-migrainous (mild or severe) 1 1 1
b. Migraine
 i. Without aura Comment: Aura is a specific focal neurologic symptom. For more 
information about this and other diagnostic criteria, see: Headache 
Classification Subcommittee of the International Headache 
Society. The international classification of headache disorders. 
2nd ed. Cephalalgia 2004;24(Suppl 1):1– 150. Available from 
http://www.i-h-s.org/upload/ct_clas/ihc_II_main_no_print.pdf.
	 	 •	Age	<35	yrs 2 2 1
	 	 •	Age	≥35	yrs 2 2 1
  ii. With aura, at any age 2 3 1
Epilepsy§ 1 1
Depressive Disorders
Depressive disorders 1 1 Clarification: The classification is based on data for women with 
selected depressive disorders. No data were available on bipolar 
disorder or postpartum depression. Drug interactions potentially 
can occur between certain antidepressant medications and hor-
monal contraceptives.
Reproductive Tract Infections and Disorders
Vaginal bleeding patterns Initiation Continuation
a. Irregular pattern without heavy bleeding 1 1 1
b. Heavy or prolonged bleeding (includes 
regular and irregular patterns)
1 2 2 Clarification: Unusually heavy bleeding should raise suspicion of 
a serious underlying condition.
Evidence: Evidence from studies examining the treatment effects 
of the LNG-IUD among women with heavy or prolonged bleeding 
reported no increase in adverse effects and found the LNG-IUD to 
be beneficial in treating menorrhagia (69–76).
Unexplained vaginal bleeding (suspicion 
for serious condition)
Clarification: If pregnancy or an underlying pathological condition 
(such as pelvic malignancy) is suspected, it must be evaluated 
and the category adjusted after evaluation. The IUD does not 
need to be removed before evaluation.
Initiation Continuation Initiation Continuation
Before evaluation 4 2 4 2
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TABLE. (Continued) Classifications for intrauterine devices,*† including the LNG-IUD and the Cu-IUD
Condition
Category
Clarifications/Evidence/CommentsLNG-IUD Cu-IUD
Endometriosis 1 2 Evidence: LNG-IUD use among women with endometriosis de-
creased dysmenorrhea, pelvic pain, and dyspareunia (77–81).
Benign ovarian tumors (including cysts) 1 1
Severe dysmenorrhea 1 2 Comment: Dysmenorrhea might intensify with Cu-IUD use. LNG-
IUD use has been associated with reduction of dysmenorrhea.
Gestational trophoblastic disease
a. Decreasing or undetectable β–hCG 
levels
3 3 Evidence: Limited evidence suggests that women using an IUD 
after uterine evacuation for a molar pregnancy are not at greater 
risk for postmolar trophoblastic disease than are women using 
other methods of contraception (82–84).
b. Persistently elevated β-hCG levels or 
malignant disease§
4 4 Evidence: Limited evidence suggests that women using an IUD 
after uterine evacuation for a molar pregnancy are not at greater 
risk for postmolar trophoblastic disease than are women using 
other methods of contraception (82–84)
Cervical ectropion 1 1
Cervical intraepithelial neoplasia 2 1 Comment: Theoretical concern exists that LNG-IUDs might 
enhance progression of cervical intraepithelial neoplasia.
Cervical cancer (awaiting treatment) Initiation Continuation Initiation Continuation Comment: Concern exists about the increased risk for infection 
and bleeding at insertion. The IUD most likely will need to be 
removed at the time of treatment, but until then, the woman is at 
risk for pregnancy.
4 2 4 2
Breast disease
a. Undiagnosed mass 2 1
b. Benign breast disease 1 1
c. Family history of cancer 1 1
d. Breast cancer§ Comment: Breast cancer is a hormonally sensitive tumor. 
Concerns about progression of the disease might be less with 
LNG-IUDs than with COCs or higher-dose POCs.
 i. Current 4 1
 ii. Past and no evidence of current 
disease for 5 yrs 
3 1
Endometrial hyperplasia 1 1 Evidence: Among women with endometrial hyperplasia, no 
adverse health events occurred with LNG-IUD use; most women 
experienced disease regression (85–93).
Endometrial cancer§ Initiation Continuation Initiation Continuation Comment: Concern exists about the increased risk for infection, 
perforation, and bleeding at insertion. The IUD most likely will 
need to be removed at the time of treatment, but until then, the 
woman is at risk for pregnancy.
4 2 4 2
Ovarian cancer§ 1 1 Comment: Women with ovarian cancer who undergo fertility spar-
ing treatment and need contraception may use an IUD.
Uterine fibroids 2 2 Evidence: Among women with uterine fibroids using an LNG-IUD, 
most experienced improvements in serum levels of hemoglobin, 
hematocrit, and ferritin (73,94–100) and menstrual blood loss 
(73,75,94–101). Rates of LNG-IUD expulsion were higher in 
women with uterine fibroids (11%) than in women without fibroids 
(0%–3%); these findings were not statistically significant or sig-
nificance testing was not conducted (75,101). Rates of expulsion 
from noncomparative studies ranged from 0%–20% (94,96–100).
Comment: Women with heavy or prolonged bleeding should be 
assigned the category for that condition.
Anatomical abnormalities
a. Distorted uterine cavity (any congenital 
or acquired uterine abnormality distort-
ing the uterine cavity in a manner that is 
incompatible with IUD insertion)
4 4 Comment: An anatomic abnormality that distorts the uterine cav-
ity might preclude proper IUD placement.
b. Other abnormalities (including cervical 
stenosis or cervical lacerations) not 
distorting the uterine cavity or interfering 
with IUD insertion
2 2
Vol. 59 Early Release 57
TABLE. (Continued) Classifications for intrauterine devices,*† including the LNG-IUD and the Cu-IUD
Condition
Category
Clarifications/Evidence/CommentsLNG-IUD Cu-IUD
Pelvic inflammatory disease (PID) Initiation Continuation Initiation Continuation
a. Past PID (assuming no known current 
risk factors for STIs)
Comment: IUDs do not protect against STI/HIV/PID. In women 
at low risk for STIs, IUD insertion poses little risk for PID. Current 
risk for STIs and desire for future pregnancy are relevant 
considerations.
 i. With subsequent pregnancy 1 1 1 1
 ii. Without subsequent pregnancy 2 2 2 2
b. Current PID 4 2 4 2 Clarification for continuation: Treat the PID using appropri-
ate antibiotics. The IUD usually does not need to be removed if 
the woman wishes to continue using it. Continued use of an IUD 
depends on the woman’s informed choice and her current risk 
factors for STIs and PID.
Evidence: Among IUD users treated for PID, clinical course did 
not differ regardless of whether the IUD was removed or left in 
place (102–104).
STIs Initiation Continuation Initiation Continuation
a. Current purulent cervicitis or chlamydial 
infection or gonorrhea
4 2 4 2 Clarification for continuation: Treat the STI using appropri-
ate antibiotics. The IUD usually does not need to be removed if 
the woman wishes to continue using it. Continued use of an IUD 
depends on the woman’s informed choice and her current risk 
factors for STIs and PID.
Evidence: No evidence exists about whether IUD insertion among 
women with STIs increases the risk for PID over that of women 
with no IUD insertion. Among women who had an IUD inserted, 
the absolute risk for subsequent PID was low among women with 
STI at the time of insertion but greater than among women with no 
STI at the time of IUD insertion (105–111).
b. Other STIs (excluding HIV and hepatitis) 2 2 2 2
c. Vaginitis (including Trichomonas 
vaginalis and bacterial vaginosis)
2 2 2 2
d. Increased risk for STIs 2/3 2 2/3 2 Clarification for initiation: If a woman has a very high individual 
likelihood of exposure to gonorrhea or chlamydial infection, the 
condition is a Category 3.
Evidence: Using an algorithm to classify STI risk status among 
IUD users, 1 study reported that 11% of women at high risk for 
STIs experienced IUD-related complications compared with 5% of 
those not classified as high risk (107).
HIV/AIDS
High risk for HIV Initiation Continuation Initiation Continuation
2 2 2 2 Evidence: Among women at risk for HIV, Cu-IUD use did not 
increase risk for HIV acquisition (112–122).
HIV infection§ 2 2 2 2 Evidence: Among IUD users, limited evidence shows no higher 
risk for overall complications or for infectious complications in HIV-
infected than in HIV-uninfected women. IUD use did not adversely 
affect progression of HIV when compared with hormonal contra-
ceptive use among HIV-infected women. Furthermore, IUD use 
among HIV-infected women was not associated with increased 
risk for transmission to sex partners (112,123–130).
AIDS§ 3 2 3 2 Clarification for continuation: IUD users with AIDS should be 
closely monitored for pelvic infection.
Clinically well on ARV therapy 2 2 2 2
Other Infections
Schistosomiasis
a. Uncomplicated 1 1
b. Fibrosis of the liver§ (if severe, see 
cirrhosis)
1 1
Tuberculosis§ Initiation Continuation Initiation Continuation
a. Nonpelvic 1 1 1 1
b. Pelvic 4 3 4 3 Comment: Insertion of an IUD may substantially worsen the 
condition.
Malaria 1 1
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TABLE. (Continued) Classifications for intrauterine devices,*† including the LNG-IUD and the Cu-IUD
Condition
Category
Clarifications/Evidence/CommentsLNG-IUD Cu-IUD
Endocrine Conditions
Diabetes
a. History of gestational disease 1 1
b. Nonvascular disease Evidence: Limited evidence on the use of the LNG-IUD among 
women with insulin-dependent or noninsulin-dependent diabetes 
suggests that these methods have little effect on short-term or 
long-term diabetes control (e.g., glycosylated hemoglobin levels), 
hemostatic markers, or lipid profile (131,132).
 i. Noninsulin-dependent 2 1
 ii. Insulin-dependent§ 2 1
c. Nephropathy/retinopathy/neuropathy§ 2 1
d. Other vascular disease or diabetes of 
>20 yrs’ duration§
2 1
Thyroid disorders
a. Simple goiter 1 1
b. Hyperthyroid 1 1
c. Hypothyroid 1 1
Gastrointestinal Conditions
Inflammatory bowel disease (IBD) 
(ulcerative colitis, Crohn disease)
1 1 Evidence: Although two case reports described three women with 
IBD who experienced exacerbation of disease 5 days–25 months 
after LNG-IUD insertion (133,134), no comparative studies have 
examined the safety of IUD use among women with IBD.
Gallbladder disease
a. Symptomatic
 i. Treated by cholecystectomy 2 1
 ii. Medically treated 2 1
 iii. Current 2 1
b. Asymptomatic 2 1
History of cholestasis
a. Pregnancy-related 1 1
b. Past COC-related 2 1 Comment: Concern exists that history of COC-related cholestasis 
might predict subsequent cholestasis with LNG use. Whether risk 
exists with use of LNG-IUD is unclear.
Viral hepatitis
a. Acute or flare 1 1
b. Carrier 1 1
c. Chronic 1 1
Cirrhosis
a. Mild (compensated) 1 1
b. Severe§ (decompensated) 3 1
Liver tumors
a. Benign 2 1
 i. Focal nodular hyperplasia
 ii. Hepatocellular adenoma§ 3 1 Comment: No evidence is available about hormonal contracep-
tive use in women with hepatocellular adenoma. COC use in 
healthy women is associated with development and growth of 
hepatocellular adenoma; whether other hormonal contraceptives 
have similar effects is not known.
b. Malignant§ (hepatoma) 3 1
Anemias
Thalassemia 1 2 Comment: Concern exists about an increased risk for blood loss 
with Cu-IUDs.
Sickle cell disease§ 1 2 Comment: Concern exists about an increased risk for blood loss 
with Cu-IUDs.
Iron deficiency anemia 1 2 Comment: Concern exists about an increased risk for blood loss 
with Cu-IUDs.
Solid Organ Transplantation
Solid organ transplantation§ Initiation Continuation Initiation Continuation Evidence: No comparative studies have examined IUD use 
among transplant patients. Four case reports of transplant 
patients using IUDs provided inconsistent results, including ben-
eficial effects and contraceptive failures (135–138).
a. Complicated: graft failure (acute or 
chronic), rejection, cardiac allograft 
vasculopathy
3 2 3 2
b. Uncomplicated 2 2 2 2
Vol. 59 Early Release 59
TABLE. (Continued) Classifications for intrauterine devices,*† including the LNG-IUD and the Cu-IUD
Condition
Category
Clarifications/Evidence/CommentsLNG-IUD Cu-IUD
Drug Interactions
Antiretroviral (ARV) therapy Initiation Continuation Initiation Continuation Clarification: No known interaction exists between ARV therapy 
and IUD use. However, AIDS as a condition is classified as 
Category 3 for insertion and Category 2 for continuation unless 
the woman is clinically well on ARV therapy, in which case, both 
insertion and continuation are classified as Category 2 (see AIDS 
condition).
a. Nucleoside reverse transcriptase inhibi-
tors (NRTIs)
2/3 2 2/3 2
b. Non-nucleoside reverse transcriptase 
inhibitors (NNRTIs)
2/3 2 2/3 2
c. Ritonavir-boosted protease inhibitors 2/3 2 2/3 2
Anticonvulsant therapy
a. Certain anticonvulsants (phenytoin, 
carbamazepine, barbiturates, primidone, 
topiramate, oxcarbazepine)
1 1 Evidence: Limited evidence suggests use of certain anticonvul-
sants does not interfere with the contraceptive effectiveness of the 
LNG-IUD (139).
b Lamotrigine 1 1 Evidence: No drug interactions have been reported among epi-
leptic women taking lamotrigine and using the LNG-IUD (140).
Antimicrobial therapy
a. Broad-spectrum antibiotics 1 1
b. Antifungals 1 1
c. Antiparasitics 1 1
d. Rifampicin or rifabutin therapy 1 1 Evidence: One cross-sectional survey found that rifabutin had no 
impact on the effectiveness of the LNG-IUD (139).
*	Abbreviations:	LNG-IUD	=	levonorgestrel-releasing	intrauterine	device;	Cu-IUD	=	copper	IUD;	STI	=	sexually	transmitted	infection;	HIV	=	human	immunodeficiency	virus;	BMI	=	
body mass index; DVT = deep venous thrombosis; PE = pulmonary embolism; POC = progestin-only contraceptive; COC = combined oral contraceptive; SLE = systemic lupus 
erythematosus;	MEC	=	Medical	Eligibility	Criteria;	hCG	=	human	chorionic	gonadotropin;	PID	=	pelvic	inflammatory	disease;	AIDS	=	acquired	immunodeficiency	syndrome;	
ARV	=	antiretroviral;	IBD	=	inflammatory	bowel	disease;	NRTI	=	nucleoside	reverse	transcriptase	inhibitor;	NNRTI	=	non-nucleoside	reverse	transcriptase	inhibitor.
† IUDs	do	not	protect	against	STI/HIV.	If	risk	exists	for	STI/HIV	(including	during	pregnancy	or	postpartum),	the	correct	and	consistent	use	of	condoms	is	recommended,	either	
alone	or	with	another	contraceptive	method.	Consistent	and	correct	use	of	the	male	latex	condom	reduces	the	risk	for	STIs	and	HIV	transmission
§ Condition	that	exposes	a	woman	to	increased	risk	as	a	result	of	unintended	pregnancy.
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BOX. Categories for Classifying Cu-IUDs as Emergency Contraception
1 = A condition for which there is no restriction for the use of the contraceptive method.
2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.
3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.
4 = A condition that represents an unacceptable health risk if the contraceptive method is used.
Appendix F
Classifications for Copper Intrauterine Devices for 
Emergency Contraception
A copper IUD (Cu-IUD) can be used within 5 days of 
unprotected intercourse as an emergency contraceptive. 
However, when the time of ovulation can be estimated, the 
Cu-IUD can be inserted beyond 5 days after intercourse, if 
necessary, as long as the insertion does not occur >5 days after 
ovulation.
The eligibility criteria for interval Cu-IUD insertion also 
apply for the insertion of Cu-IUDs as emergency contracep-
tion (Box). Cu-IUDs for emergency contraception do not 
protect against sexually transmitted infections (STIs) or human 
immunodeficiency virus (HIV).
TABLE. Classifications for copper intrauterine devices for emergency contraception*†
Condition Category Clarifications/Evidence/Comments
Pregnancy 4 Clarification: IUD use is not indicated during pregnancy and should not be used because 
of the risk for serious pelvic infection and septic spontaneous abortion.
Rape
a. High risk for STI 3 Comment: IUDs do not protect against STI/HIV or PID. Among women with chlamydial 
infection or gonorrhea, the potential increased risk for PID with IUD insertion should be 
avoided. The concern is less for other STIs.
b. Low risk for STI 1
* Abbreviations: IUD = intrauterine device; Cu-IUD = copper IUD; STI = sexually transmitted infection; HIV = human immunodeficiency virus; PID = pelvic 
inflammatory disease
† Cu-IUDs for emergency contraception do not protect against STI/HIV. If risk exists for STI/HIV (including during pregnancy or postpartum), the correct 
and consistent use of condoms is recommended, either alone or with another contraceptive method. Consistent and correct use of the male latex condom 
reduces the risk for STIs and HIV transmission.
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BOX. Categories for Classifying Barrier Methods
1 = A condition for which there is no restriction for the use of the contraceptive method.
2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.
3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.
4 = A condition that represents an unacceptable health risk if the contraceptive method is used.
Appendix G
 Classifications for Barrier Methods
Classifications for barrier contraceptive methods include 
those for condoms, which include male latex condoms, male 
polyurethane condoms, and female condoms; spermicides; and 
diaphragm with spermicide or cervical cap (Box). Consistent 
and correct use of the male latex condom reduces the risk for 
STI/HIV transmission.
Women with conditions that make pregnancy an unaccept-
able risk should be advised that barrier methods for pregnancy 
prevention may not be appropriate for those who cannot use 
them consistently and correctly because of the relatively higher 
typical-use failure rates of these methods.
TABLE. Classifications for barrier methods,*† including condoms, spermicides, and diaphragms/caps
Condition
Category
Clarifications/Evidence/CommentsCondom Spermicide
Diaphragm/
cap
Personal Characteristics and Reproductive History
Pregnancy Not 
applicable
Not 
applicable
Not 
applicable
Clarification: None of these methods are relevant for contraception during known 
pregnancy. However, for women who remain at risk for STI/HIV during pregnancy, 
the correct and consistent use of condoms is recommended.
Age
a. Menarche to <40 yrs 1 1 1
b. ≥40 yrs 1 1 1
Parity
a. Nulliparous 1 1 1
b. Parous 1 1 2 Clarification: Risk for cervical cap failure is higher in parous women than in 
nulliparous women.
Postpartum
a. <6 wks postpartum 1 1 Not 
applicable
Clarification: Diaphragm and cap are unsuitable until uterine involution is 
complete.
b. ≥6 wks postpartum 1 1 1
Postabortion
a. First trimester 1 1 1
b. Second trimester 1 1 1 Clarification: Diaphragm and cap are unsuitable until 6 weeks after second 
trimester abortion.
c. Immediate postseptic abortion 1 1 1
Past ectopic pregnancy 1 1 1
History of pelvic surgery 1 1 1
Smoking
a. Age <35 yrs 1 1 1
b. Age ≥35 yrs
 i. <15 Cigarettes/day 1 1 1
 ii. ≥15 Cigarettes/day 1 1 1
Obesity Comment: Severe obesity might make diaphragm and cap placement difficult.
a. ≥30 kg/m2 BMI 1 1 1
b. Menarche to <18 yrs and ≥30 kg/m2 BMI 1 1 1
History of bariatric surgery§
a. Restrictive procedures: decrease storage 
capacity of the stomach (vertical banded gas-
troplasty, laparoscopic adjustable gastric band, 
laparoscopic sleeve gastrectomy)
1 1 1
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TABLE. (Continued) Classifications for barrier methods,*† including condoms, spermicides, and diaphragms/caps
Condition
Category
Clarifications/Evidence/CommentsCondom Spermicide
Diaphragm/
cap
b. Malabsorptive procedures: decrease absorp-
tion of nutrients and calories by shortening the 
functional length of the small intestine (Roux-
en-Y gastric bypass, biliopancreatic diversion)
1 1 1
Cardiovascular Disease
Multiple risk factors for arterial cardiovascular 
disease (such as older age, smoking, diabetes, 
and hypertension)
1 1 1
Hypertension
a. Adequately controlled hypertension 1 1 1
b. Elevated blood pressure levels (properly taken 
measurements)
 i. Systolic 140–159 mm Hg or 
diastolic 90–99 mm Hg
1 1 1
 ii. Systolic ≥160 mm Hg or diastolic ≥100 mm 
Hg§
1 1 1
c. Vascular disease 1 1 1
History of high blood pressure during 
pregnancy (where current blood pressure is 
measurable and normal)
1 1 1
Deep venous thrombosis (DVT)/pulmonary 
embolism (PE)
a. History of DVT/PE, not on anticoagulant 
therapy
 i. Higher risk for recurrent DVT/PE (≥1 risk 
factors)
	 •	 History	of	estrogen-associated	DVT/PE
	 •	 Pregnancy-associated	DVT/PE
	 •	 Idiopathic	DVT/PE
	 •	 Known	thrombophilia,	including	antiphos-
pholipid syndrome
	 •	 Active	cancer	(metastatic,	on	therapy,	
or within 6 mos after clinical remission), 
excluding non-melanoma skin cancer
	 •	 History	of	recurrent	DVT/PE
1 1 1
 ii. Lower risk for recurrent DVT/PE (no risk 
factors)
1 1 1
b. Acute DVT/PE 1 1 1
c. DVT/PE and established on anticoagulant 
therapy for at least 3 mos
 i. Higher risk for recurrent DVT/PE (≥1 risk 
factors)
	 •	 Known	thrombophilia,	including	antiphos-
pholipid syndrome
	 •	 Active	cancer	(metastatic,	on	therapy,	
or within 6 mos after clinical remission), 
excluding non-melanoma skin cancer
	 •	 History	of	recurrent	DVT/PE
1 1 1
 ii. Lower risk for recurrent DVT/PE (no risk 
factors)
1 1 1
d. Family history (first-degree relatives) 1 1 1
e. Major surgery
 i. With prolonged immobilization 1 1 1
 ii. Without prolonged immobilization 1 1 1
f. Minor surgery without immobilization 1 1 1
Known thrombogenic mutations§ (e.g., factor V 
Leiden; prothrombin mutation; protein S, protein C, 
and antithrombin deficiencies)
1 1 1 Clarification: Routine screening is not appropriate because of the rarity of the 
conditions and the high cost of screening.
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TABLE. (Continued) Classifications for barrier methods,*† including condoms, spermicides, and diaphragms/caps
Condition
Category
Clarifications/Evidence/CommentsCondom Spermicide
Diaphragm/
cap
Superficial venous thrombosis
a. Varicose veins 1 1 1
b. Superficial thrombophlebitis 1 1 1
Current and history of ischemic heart disease§
1 1 1
Stroke§ (history of cerebrovascular accident)
1 1 1
Known hyperlipidemias 1 1 1 Clarification: Routine screening is not appropriate because of the rarity of the 
conditions and the high cost of screening.
Valvular heart disease
a. Uncomplicated 1 1 1
b. Complicated§ (pulmonary hypertension, risk for 
atrial fibrillation, history of subacute bacterial 
endocarditis)
1 1 2
Peripartum cardiomyopathy§
a. Normal or mildly impaired cardiac function 
(New York Heart Association Functional Class 
I or II: patients with no limitation of activities or 
patients with slight, mild limitation of activity) 
(1)
 i. <6 mos 1 1 1
 ii. ≥6 mos 1 1 1
b. Moderately or severely impaired cardiac func-
tion (New York Heart Association Functional 
Class III or IV: patients with marked limitation 
of activity or patients who should be at com-
plete rest) (1)
1 1 1
Rheumatic Diseases
Systemic lupus erythematosus§
a. Positive (or unknown) antiphospholipid 
antibodies
1 1 1
b. Severe thrombocytopenia 1 1 1
c. Immunosuppressive treatment 1 1 1
d. None of the above 1 1 1
Rheumatoid arthritis
a. On immunosuppressive therapy 1 1 1
b. Not on immunosuppressive therapy 1 1 1
Neurologic Conditions
Headaches
a. Non-migrainous (mild or severe) 1 1 1
b. Migraine
 i. Without aura
	 •	 Age	<35	yrs 1 1 1
	 •	 Age	≥35	yrs 1 1 1
 ii. With aura, at any age 1 1 1
Epilepsy§ 1 1 1
Depressive Disorders
Depressive disorders 1 1 1
Reproductive Tract Infections and Disorders
Unexplained vaginal bleeding 
(suspicious for serious condition)
Before evaluation 1 1 1 Clarification: If pregnancy or an underlying pathological condition (such as pelvic 
malignancy) is suspected, it must be evaluated and the category adjusted after 
evaluation.
Endometriosis 1 1 1
Benign ovarian tumors (including cysts) 1 1 1
Severe dysmenorrhea 1 1 1
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TABLE. (Continued) Classifications for barrier methods,*† including condoms, spermicides, and diaphragms/caps
Condition
Category
Clarifications/Evidence/CommentsCondom Spermicide
Diaphragm/
cap
Gestational trophoblastic disease
a. Decreasing or undetectable β–hCG levels 1 1 1
b. Persistently elevated β-hCG levels or 
malignant disease§
1 1 1
Cervical ectropion 1 1 1
Cervical intraepithelial neoplasia 1 1 1 Clarification: The cap should not be used. Diaphragm use has no restrictions.
Cervical cancer (awaiting treatment) 1 2 1 Clarification: The cap should not be used. Diaphragm use has no restrictions.
Comment: Repeated and high-dose use of nonoxynol-9 can cause vaginal and 
cervical irritation or abrasions.
Breast disease
a. Undiagnosed mass 1 1 1
b. Benign breast disease 1 1 1
c. Family history of cancer 1 1 1
d. Breast cancer§
 i. Current 1 1 1
 ii. Past and no evidence of current disease 
for 5 yrs
1 1 1
Endometrial hyperplasia 1 1 1
Endometrial cancer§ 1 1 1
Ovarian cancer§ 1 1 1
Uterine fibroids 1 1 1
Anatomical abnormalities 1 1 Not 
applicable
Clarification: The diaphragm cannot be used in certain cases of prolapse. Cap 
use is not appropriate for a woman with markedly distorted cervical anatomy.
Pelvic inflammatory disease (PID)
a. Past PID (assuming no current risk factors of 
STIs)
 i. With subsequent pregnancy 1 1 1
 ii. Without subsequent pregnancy 1 1 1
b. Current PID 1 1 1
STIs
a. Current purulent cervicitis or chlamydial infec-
tion or gonorrhea
1 1 1
b. Other STIs (excluding HIV and hepatitis) 1 1 1
c. Vaginitis (including Trichomonas vaginalis and 
bacterial vaginosis)
1 1 1
d. Increased risk for STIs 1 1 1
HIV/AIDS
High risk for HIV 1 4 4 Evidence: Repeated and high-dose use of the spermicide nonoxynol-9 was as-
sociated with increased risk for genital lesions, which might increase the risk for 
HIV infection (2).
Comment: Diaphragm use is assigned Category 4 because of concerns about 
the spermicide, not the diaphragm.
HIV infection§ 1 3 3 Comment: Use of spermicides and/or diaphragms (with spermicide) can disrupt 
the cervical mucosa, which may increase viral shedding and HIV transmission to 
uninfected sex partners.
AIDS§ 1 3 3 Comment: Use of spermicides and/or diaphragms (with spermicide) can disrupt 
the cervical mucosa, which may increase viral shedding and HIV transmission to 
uninfected sex partners
Other Infections
Schistosomiasis
a. Uncomplicated 1 1 1
b. Fibrosis of liver§ 1 1 1
Tuberculosis§
a. Nonpelvic 1 1 1
b. Pelvic 1 1 1
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TABLE. (Continued) Classifications for barrier methods,*† including condoms, spermicides, and diaphragms/caps
Condition
Category
Clarifications/Evidence/CommentsCondom Spermicide
Diaphragm/
cap
Malaria 1 1 1
History of toxic shock syndrome 1 1 3 Comment: Toxic shock syndrome has been reported in association with contra-
ceptive sponge and diaphragm use.
Urinary tract infection 1 1 2 Comment: Use of diaphragms and spermicides might increase risk for urinary 
tract infection.
Endocrine Conditions
Diabetes
a. History of gestational disease 1 1 1
b. Nonvascular disease
 i. Noninsulin-dependent 1 1 1
 ii. Insulin-dependent§ 1 1 1
c. Nephropathy/retinopathy/neuropathy§ 1 1 1
d. Other vascular disease or diabetes of >20 yrs’ 
duration§
1 1 1
Thyroid disorders
a. Simple goiter 1 1 1
b. Hyperthyroid 1 1 1
c. Hypothyroid 1 1 1
Gastrointestinal Conditions
Inflammatory bowel disease 
(ulcerative colitis, Crohn disease)
1 1 1
Gallbladder disease
a. Symptomatic
 i. Treated by cholecystectomy 1 1 1
 ii. Medically treated 1 1 1
 iii. Current 1 1 1
b. Asymptomatic 1 1 1
History of cholestasis
a. Pregnancy-related 1 1 1
b. Past COC-related 1 1 1
Viral hepatitis
a. Acute or flare 1 1 1
b. Carrier 1 1 1
c. Chronic 1 1 1
Cirrhosis
a. Mild (compensated) 1 1 1
b. Severe§ (decompensated) 1 1 1
Liver tumors
a. Benign
 i. Focal nodular hyperplasia 1 1 1
 ii. Hepatocellular adenoma§ 1 1 1
b. Malignant§ (hepatoma) 1 1 1
Anemias
Thalassemia 1 1 1
Sickle cell disease§ 1 1 1
Iron deficiency anemia 1 1 1
Solid Organ Transplantation
Solid organ transplantation§
a. Complicated: graft failure (acute or chronic), 
rejection, cardiac allograft vasculopathy
1 1 1
b. Uncomplicated 1 1 1
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TABLE. (Continued) Classifications for barrier methods,*† including condoms, spermicides, and diaphragms/caps
Condition
Category
Clarifications/Evidence/CommentsCondom Spermicide
Diaphragm/
cap
Drug Interactions
Antiretroviral (ARV) therapy Clarification: No drug interaction between ARV therapy and barrier method 
use is known. However, HIV infection and AIDS are classified as Category 3 for 
spermicides and diaphragms (see HIV/AIDS condition above).
a. Nucleoside reverse transcriptase inhibitors 
(NRTIs)
1 3 3
b. Non-nucleoside reverse transcriptase 
inhibitors (NNRTIs)
1 3 3
c. Ritonavir-boosted protease inhibitors 1 3 3
Anticonvulsant therapy
a. Certain anticonvulsants (phenytoin, carbam-
azepine, barbiturates, primidone, topiramate, 
oxcarbazepine)
1 1 1
b. Lamotrigine 1 1 1
Antimicrobial therapy
a. Broad-spectrum antibiotics 1 1 1
b. Antifungals 1 1 1
c. Antiparasitics 1 1 1
d. Rifampicin or rifabutin  
therapy
1 1 1
Allergy to latex 3 1 3 Clarification: The condition of allergy to latex does not apply to plastic condoms/
diaphragms.
* Abbreviations: STI = sexually transmitted infection; HIV = human immunodeficiency virus; BMI, body mass index; DVT = deep venous thrombosis; PE = pulmonary embolism; 
ARV = antiretroviral; hCG = human chorionic gonadotropin; PID = pelvic inflammatory disease; AIDS = acquired immunodeficiency syndrome; COC = combined oral contracep-
tive; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor.
† If risk exists for STI/HIV (including during pregnancy or postpartum), the correct and consistent use of condoms is recommended, either alone or with another contraceptive 
method. Consistent and correct use of the male latex condom reduces the risk for STIs and HIV transmission. Women with conditions that make pregnancy an unacceptable 
risk should be advised that barrier methods for pregnancy prevention may not be appropriate for those who cannot use them consistently and correctly because of the relatively 
higher typical-use failure rates of these methods.
§ Condition that exposes a woman to increased risk as a result of unintended pregnancy.
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Appendix H
 Classifications for Fertility Awareness–Based Methods
Fertility awareness–based (FAB) methods of family planning 
involve identifying the fertile days of the menstrual cycle, 
whether by observing fertility signs such as cervical secretions 
and basal body temperature or by monitoring cycle days (Box). 
FAB methods can be used in combination with abstinence or 
barrier methods during the fertile time. If barrier methods are 
used, refer to Appendix G.
No medical conditions become worse because of use of FAB 
methods. In general, FAB methods can be used without con-
cern for health effects to persons who choose them. However, 
a number of conditions make their use more complex. The 
existence of these conditions suggests that 1) use of these 
methods should be delayed until the condition is corrected or 
resolved or 2) persons using FAB methods will require special 
counseling, and a more highly trained provider is generally 
necessary to ensure correct use.
Women with conditions that make pregnancy an unaccept-
able risk should be advised that FAB methods might not be 
appropriate for them because of the relatively higher typical-use 
failure rates of these methods. FAB methods do not protect 
against sexually transmitted infections (STIs) or human immu-
nodeficiency virus (HIV).
Box. Definitions for terms associated with fertility awareness–
based methods
Symptoms-based methods•	 : FAB methods based on 
observation of fertility signs (e.g., cervical secretions, basal 
body temperature) such as the Cervical Mucus Method, 
the Symptothermal Method, and the TwoDay Method.
Calendar-based methods•	 : FAB methods based on cal-
endar calculations such as the Calendar Rhythm Method 
and the Standard Days Method.
Acccept (A)•	 : There is no medical reason to deny the par-
ticular FAB method to a woman in this circumstance.
Caution (C)•	 : The method is normally provided in a 
routine setting but with extra preparation and precau-
tions. For FAB methods, this usually means that special 
counselling might be needed to ensure correct use of the 
method by a woman in this circumstance.
Delay (D)•	 : Use of this method should be delayed until the 
condition is evaluated or corrected. Alternative temporary 
methods of contraception should be offered.
TABLE. Fertility awareness–based methods,*† including symptoms-based and calendar-based methods
Condition
Category
Clarifications/Evidence/Comments
Symptom-based 
method
Calendar-based 
method
Personal Characteristics and Reproductive History
Pregnancy Not applicable Clarification: FAB methods are not relevant during pregnancy.
Life stage Clarification: Menstrual irregularities are common in postmenarche and perimeno-
pause and might complicate the use of FAB methods.
a. Postmenarche C C
b. Perimenopause C C
Breastfeeding Comment: Use of FAB methods when breastfeeding might be less effective than 
when not breastfeeding.
a. <6 wks postpartum D D Comment: Women who are primarily breastfeeding and are amenorrheic are 
unlikely to have sufficient ovarian function to produce detectable fertility signs and 
hormonal changes during the first 6 months postpartum. However, the likelihood of 
resumption of fertility increases with time postpartum and with substitution of breast 
milk with other foods.
b. ≥6 wks C D
c. After menses begin C C Comment: When the woman notices fertility signs, particularly cervical secre-
tions, she can use a symptoms-based method. First postpartum menstrual cycles 
in breastfeeding women vary significantly in length. Return to regularity takes 
several cycles. When she has had at least 3 postpartum menses and her cycles are 
regular again, she can use a calendar-based method. When she has had at least 4 
postpartum menses and her most recent cycle lasted 26–32 days, she can use the 
Standard Days Method. Before that time, a barrier method should be offered if the 
woman plans to use a FAB method later.
72 Early Release May 28, 2010
TABLE. (Continued) Fertility awareness–based methods,*† including symptoms-based and calendar-based methods
Condition
Category
Clarifications/Evidence/Comments
Symptom-based 
method
Calendar-based 
method
Postpartum (in nonbreastfeeding women)
a. <4 wks D D Comment: Nonbreastfeeding women are not likely to have sufficient ovarian func-
tion to either require a FAB method or to have detectable fertility signs or hormonal 
changes before 4 weeks postpartum. Although the risk for pregnancy is low, a 
method appropriate for the postpartum period should be offered.
b. ≥4 wks A D Comment: Nonbreastfeeding women are likely to have sufficient ovarian function 
to produce detectable fertility signs and/or hormonal changes at this time; likelihood 
increases rapidly with time postpartum. Women can use calendar-based methods 
as soon as they have completed three postpartum menses. Methods appropriate for 
the postpartum period should be offered before that time.
Postabortion C D Comment: Postabortion women are likely to have sufficient ovarian function to 
produce detectable fertility signs and/or hormonal changes; likelihood increases 
with time postabortion. Women can start using calendar-based methods after they 
have had at least 1 postabortion menses (e.g., women who before this pregnancy 
had most cycles of 26–32 days can then use the Standard Days Method). Methods 
appropriate for the postabortion period should be offered before that time.
Reproductive Tract Infections and Disorders
Irregular vaginal bleeding D D Comment: Presence of this condition makes FAB methods unreliable. Therefore, 
barrier methods should be recommended until the bleeding pattern is compat-
ible with proper method use. The condition should be evaluated and treated as 
necessary.
Vaginal discharge D A Comment: Because vaginal discharge makes recognition of cervical secretions 
difficult, the condition should be evaluated and treated if needed before providing 
methods based on cervical secretions.
Other
Use of drugs that affect cycle regularity, 
hormones, and/or fertility signs
C/D C/D Comment: Use of certain mood-altering drugs such as lithium, tricyclic antidepres-
sants, and antianxiety therapies, and certain antibiotics and anti-inflammatory 
drugs, might alter cycle regularity or affect fertility signs. The condition should be 
carefully evaluated and a barrier method offered until the degree of effect has been 
determined or the drug is no longer being used.
Diseases that elevate body temperature
a. Chronic diseases C A Comment: Elevated temperature levels might make basal body temperature dif-
ficult to interpret but have no effect on cervical secretions. Thus, use of a method 
that relies on temperature should be delayed until the acute febrile disease abates. 
Temperature-based methods are not appropriate for women with chronically elevat-
ed temperatures. In addition, some chronic diseases interfere with cycle regularity, 
making calendar-based methods difficult to interpret.
b. Acute diseases D A
* Abbreviations: FAB = fertility awareness–based; A = accept; C = caution; D = delay; STI = sexually transmitted infection; HIV = human immunodeficiency infection.
† Fertility awareness–based methods do not protect against STI/HIV. If risk exists for STI/HIV (including during pregnancy or postpartum), the correct and consistent use of condoms 
is recommended, either alone or with another contraceptive method. Consistent and correct use of the male latex condom reduces the risk for STIs and HIV transmission.
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The Bellagio Consensus provided the scientific basis for 
defining the conditions under which breastfeeding can be 
used safely and effectively for birth-spacing purposes, and 
programmatic guidelines were developed for use of lacta-
tional amenorrhea in family planning (1,2). These guidelines 
include the following three criteria, all of which must be met 
to ensure adequate protection from an unplanned pregnancy: 
1) amenorrhea; 2) fully or nearly fully breastfeeding, and 3) 
<6 months postpartum.
The main indications for breastfeeding are to provide an ideal 
food for the infant and protect against disease. No medical 
conditions exist for which use of the lactational amenorrhea 
method for contraception is restricted. However, breastfeed-
ing might not be recommended for women or infants with 
certain conditions. 
Women with conditions that make pregnancy an unac-
ceptable risk should be advised that the lactational amenor-
rhea method might not be appropriate for them because of 
its relatively higher typical-use failure rates. The lactational 
amenorrhea method does not protect against sexually trans-
mitted infections (STIs) and human immunodeficiency virus 
(HIV). If risk exists for STI/HIV (including during pregnancy 
or postpartum), the correct and consistent use of condoms 
is recommended, either alone or with another contraceptive 
method. Consistent and correct use of the male latex condom 
reduces the risk for STIs and HIV transmission. 
HIV Infection
HIV can be transmitted from mother to infant through 
breastfeeding. Therefore, in the United States, where replace-
ment feeding is affordable, feasible, acceptable, sustainable, 
and safe, breastfeeding for women with HIV is not recom-
mended (3,4).
Other Medical Conditions
The American Academy of Pediatrics also recommends 
against breastfeeding for women with active untreated tuber-
culosis disease, who are positive for human T-cell lymphotropic 
virus types I or II, or who have herpes simplex lesions on a 
breast (infant can feed from the other breast). In addition, 
infants with classic galactosemia should not breastfeed (4).
Medication Used during Breastfeeding
To protect infant health, the American Academy of Pediatrics 
does not recommend breastfeeding for women receiving certain 
drugs, including diagnostic or therapeutic radioactive isotopes 
or exposure to radioactive materials, antimetabolites or chemo-
therapeutic agents, and current use of drugs of abuse (4).
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Coitus interruptus (CI), also known as withdrawal, is a tra-
ditional family planning method in which the man completely 
removes his penis from the vagina, and away from the external 
genitalia of the female partner, before he ejaculates. CI prevents 
sperm from entering the woman’s vagina, thereby preventing 
contact between spermatozoa and the ovum.
This method might be appropriate for couples
who are highly motivated and able to use this method •	
effectively;
with religious or philosophical reasons for not using other •	
methods of contraception;
who need contraception immediately and have entered •	
into a sexual act without alternative methods available;
who need a temporary method while awaiting the start of •	
another method; or
who have intercourse infrequently.•	
Some benefits of CI are that the method, if used correctly, 
does not affect breastfeeding and is always available for primary 
use or use as a back-up method. In addition, CI involves no 
economic cost or use of chemicals. CI has no directly associated 
health risks. CI does not protect against sexually transmitted 
infections (STIs) and human immunodeficiency virus (HIV). 
If risk exists for STI/HIV (including during pregnancy or 
postpartum), the correct and consistent use of condoms is 
recommended, either alone or with another contraceptive 
method. Consistent and correct use of the male latex condom 
reduces the risk for STIs and HIV transmission.
CI is unforgiving of incorrect use, and its effectiveness 
depends on the willingness and ability of the couple to use 
withdrawal with every act of intercourse. Women with con-
ditions that make pregnancy an unacceptable risk should be 
advised that CI might not be appropriate for them because of 
its relatively higher typical-use failure rates.
Appendix J
Coitus Interruptus (Withdrawal)
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Tubal sterilization for women and vasectomy for men are 
permanent, safe, and highly effective methods of contraception. 
In general, no medical conditions would absolutely restrict 
a person’s eligibility for sterilization (with the exception of 
known allergy or hypersensitivity to any materials used to 
complete the sterilization method). However, certain condi-
tions place a woman at high surgical risk; in these cases, careful 
consideration should be given to the risks and benefits of other 
acceptable alternatives, including long-acting, highly effective, 
reversible methods and vasectomy. Female and male steriliza-
tion do not protect against sexually transmitted infections 
(STIs) or human immunodeficiency virus (HIV). If risk exists 
for STI/HIV (including during pregnancy or postpartum), the 
correct and consistent use of condoms is recommended, either 
alone or with another contraceptive method. Consistent and 
correct use of the male latex condom reduces the risk for STIs 
and HIV transmission.
Because these methods are intended to be irreversible, per-
sons who choose sterilization should be certain that they want 
to prevent pregnancy permanently. Most persons who choose 
sterilization remain satisfied with their decision. However, a 
small proportion of women regret this decision (1%–26% from 
different studies, with higher rates of regret reported by women 
who were younger at sterilization) (1,2). Regret among men 
about vasectomy has been reported to be approximately 5% 
(3), similar to the proportion of women who report regretting 
their husbands’ vasectomy (6%) (4). Therefore, all persons 
should be appropriately counseled about the permanency of 
sterilization and the availability of highly effective, reversible 
methods of contraception.
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BOX. Categories for Classifying Hormonal Contraceptives and IUDs
1 = A condition for which there is no restriction for the use of the contraceptive method.
2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.
3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.
4 = A condition that represents an unacceptable health risk if the contraceptive method is used.
Appendix L
 Summary of Classifications for Hormonal Contraceptive Methods and 
Intrauterine Devices
TABLE. Summary of classifications for hormonal contraceptive methods and intrauterine devices*
Condition COC/P/R POP DMPA Implants LNG-IUD Cu-IUD
Personal Characteristics and Reproductive History
Pregnancy Not applicable† Not applicable† Not applicable† Not applicable† 4† 4†
Age Menarche to 
<40 yrs = 1
Menarche to 
<18 yrs = 1
Menarche to 
<18 yrs = 2
Menarche to 
<18 yrs =1
Menarche to 
<20 yrs = 2
Menarche to 
<20 yrs = 2
≥40 yrs = 2 18–45 yrs = 1 18–45 yrs = 1 18–45 yrs = 1 ≥20 yrs = 1 ≥20 yrs = 1
>45 yrs = 1 >45 yrs = 2 >45 yrs = 1
Parity
a. Nulliparous 1 1 1 1 2 2
b. Parous 1 1 1 1 1 1
Breastfeeding
a. <1 mo postpartum 3† 2† 2† 2†
b. 1 mo to <6 mos 2† 1† 1† 1†
c. ≥6 mos postpartum 2† 1† 1† 1†
Postpartum 
(nonbreastfeeding women)
a. <21 days 3 1 1 1
b. ≥21 days 1 1 1 1
Postpartum (breastfeeding or 
nonbreastfeeding women, including 
post-Cesarean section)
a. <10 min after delivery of the 
placenta
2 1
b. 10 min after delivery of the pla-
centa to <4 wks
2 2
c. ≥4 wks 1 1
d. Puerperal sepsis 4 4
Postabortion
a. First trimester 1† 1† 1† 1† 1† 1†
b. Second trimester 1† 1† 1† 1† 2 2
c. Immediate postseptic abortion 1† 1† 1† 1† 4 4
Past ectopic pregnancy 1 2 1 1 1 1
History of pelvic surgery (see post-
partum, including Cesarean section)
1 1 1 1 1 1
Smoking
a. Age <35 yrs 2 1 1 1 1 1
b. Age ≥35 yrs
 i. <15 Cigarettes/day 3 1 1 1 1 1
 ii. ≥15 Cigarettes/day 4 1 1 1 1 1
Health-care providers can use the summary table as a quick 
reference guide to the classifications for hormonal contracep-
tive methods and intrauterine contraception and to compare 
classifications across these methods. See the full appendix for 
each method for clarifications to the numeric categories, as well 
as for summaries of the evidence and additional comments.
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TABLE. (Continued) Summary of classifications for hormonal contraceptive methods and intrauterine devices*
Condition COC/P/R POP DMPA Implants LNG-IUD Cu-IUD
Obesity
a. ≥30 kg/m2 BMI 2 1 1 1 1 1
b. Menarche to <18 yrs and 
≥30 kg/m2 BMI
2 1 2 1 1 1
History of bariatric surgery§
a. Restrictive procedures: decrease 
storage capacity of the stomach 
(vertical banded gastroplasty, lap-
aroscopic adjustable gastric band, 
laparoscopic sleeve gastrectomy)
1 1 1 1 1 1
b. Malabsorptive procedures: 
decrease absorption of nutrients 
and calories by shortening the 
functional length of the small in-
testine (Roux-en-Y gastric bypass, 
biliopancreatic diversion)
COCs: 3 
P/R: 1
3 1 1 1 1
Cardiovascular Disease
Multiple risk factors for arterial 
cardiovascular disease (such as 
older age, smoking, diabetes, and 
hypertension)
3/4† 2† 3† 2† 2 1
Hypertension
a. Adequately controlled 
hypertension
3† 1† 2† 1† 1 1
b. Elevated blood pressure levels 
(properly taken measurements)
 i. Systolic 140–159 mm Hg or 
diastolic 90–99 mm Hg
3 1 2 1 1 1
 ii. Systolic ≥160 mm Hg or 
diastolic ≥100 mm Hg§
4 2 3 2 2 1
c. Vascular disease 4 2 3 2 2 1
History of high blood pressure dur-
ing pregnancy (where current blood 
pressure is measurable and normal)
2 1 1 1 1 1
Deep venous thrombosis (DVT)/ 
pulmonary embolism (PE)
a. History of DVT/PE, not on 
anticoagulant therapy
 i. Higher risk for recurrent DVT/
PE (≥1 risk factors)
4 2 2 2 2 1
	 •	 History	of	estrogen- 
associated DVT/PE
	 •	 Pregnancy-associated	
DVT/PE
	 •	 Idiopathic	DVT/PE
	 •	 Known	thrombophilia,	
including antiphospholipid 
syndrome
	 •	 Active	cancer	(metastatic,	on	
therapy, or within 6 mos after 
clinical remission), excluding 
non-melanoma skin cancer
	 •	 History	of	recurrent	DVT/PE
ii. Lower risk for recurrent DVT/PE 
(no risk factors)
3 2 2 2 2 1
b. Acute DVT/PE 4 2 2 2 2 2
c. DVT/PE and established on 
anticoagulant therapy for at least 3 
mos
 i. Higher risk for recurrent DVT/
PE (≥1 risk factors)
4† 2 2 2 2 2
	 •	 Known	thrombophilia,	
including antiphospholipid 
syndrome
	 •	 Active	cancer	(metastatic,	on	
therapy, or within 6 mos after 
clinical remission), excluding 
non-melanoma skin cancer
	 •	 History	of	recurrent	DVT/PE
 ii. Lower risk for recurrent DVT/
PE (no risk factors)
3† 2 2 2 2 2
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TABLE. (Continued) Summary of classifications for hormonal contraceptive methods and intrauterine devices*
Condition COC/P/R POP DMPA Implants LNG-IUD Cu-IUD
d. Family history (first-degree 
relatives)
2 1 1 1 1 1
e. Major surgery
 i. With prolonged immobilization 4 2 2 2 2 1
 ii. Without prolonged 
immobilization
2 1 1 1 1 1
f. Minor surgery without 
immobilization
1 1 1 1 1 1
Known thrombogenic mutations§ 
(e.g. factor V Leiden; prothrombin 
mutation; protein S, protein C, and 
antithrombin deficiencies)
4† 2† 2† 2† 2† 1†
Superficial venous thrombosis
a. Varicose veins 1 1 1 1 1 1
b. Superficial thrombophlebitis 2 1 1 1 1 1
Current and history of ischemic 
heart disease§
Initiation Continuation Initiation Continuation Initiation Continuation
4 2 3 3 2 3 2 3 1
Stroke§ (history of cerebrovascular 
accident)
Initiation Continuation Initiation Continuation
4 2 3 3 2 3 2 1
Known hyperlipidemias 2/3† 2† 2† 2† 2† 1†
Valvular heart disease
a. Uncomplicated 2 1 1 1 1 1
b. Complicated§ (pulmonary hyper-
tension, risk for atrial fibrillation, 
history of subacute bacterial 
endocarditis)
4 1 1 1 1 1
Peripartum cardiomyopathy§
a. Normal or mildly impaired car-
diac function (New York Heart 
Association Functional Class I or 
II: patients with no limitation of 
activities or patients with slight, 
mild limitation of activity) (1)
 i. <6 mos 4 1 1 1 2 2
 ii. ≥6 mos 3 1 1 1 2 2
b. Moderately or severely impaired 
cardiac function (New York Heart 
Association Functional Class III or 
IV: patients with marked limitation 
of activity or patients who should 
be at complete rest) (1)
4 2 2 2 2 2
Rheumatic Diseases
Systemic lupus erythematosus§ Initiation Continuation Initiation Continuation
a.  Positive (or unknown) antiphos-
pholipid antibodies
4 3 3 3 3 3 1 1
b.  Severe thrombocytopenia 2 2 3 2 2 2† 3† 2†
c.  Immunosuppressive treatment 2 2 2 2 2 2 2 1
d.  None of the above 2 2 2 2 2 2 1 1
Rheumatoid arthritis Initiation Continuation Initiation Continuation
a. On immunosuppressive therapy 2 1 2/3† 1 2 1 2 1
b. Not on immunosuppressive 
therapy
2 1 2 1 1 1
Neurologic Conditions
Headaches Initiation Continuation Initiation Continuation Initiation Continuation Initiation Continuation Initiation Continuation
a. Non-migrainous (mild or severe) 1† 2† 1† 1† 1† 1† 1† 1† 1† 1† 1†
b. Migraine
 i. Without aura
	 •	 Age	<35	yrs 2† 3† 1† 2† 2† 2† 2† 2† 2† 2† 1†
	 •	 Age	≥35 yrs 3† 4† 1† 2† 2† 2† 2† 2† 2† 2† 1†
 ii. With aura (at any age) 4† 4† 2† 3† 2† 3† 2† 3† 2† 3† 1†
Epilepsy§ 1† 1† 1† 1† 1 1
If on treatment, see Drug Interactions section below
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TABLE. (Continued) Summary of classifications for hormonal contraceptive methods and intrauterine devices*
Condition COC/P/R POP DMPA Implants LNG-IUD Cu-IUD
Depressive Disorders
Depressive disorders 1† 1† 1† 1† 1† 1†
Reproductive Tract Infections and Disorders
Vaginal bleeding patterns Initiation Continuation
a. Irregular pattern without heavy 
bleeding
1 2 2 2 1 1 1
b. Heavy or prolonged bleeding 
(includes regular and irregular 
patterns)
1† 2† 2† 2† 1† 2† 2†
Unexplained vaginal bleeding (sus-
picious for serious condition)
Initiation Continuation Initiation Continuation
Before evaluation 2† 2† 3† 3† 4† 2† 4† 2†
Endometriosis 1 1 1 1 1 2
Benign ovarian tumors (including 
cysts)
1 1 1 1 1 1
Severe dysmenorrhea 1 1 1 1 1 2
Gestational trophoblastic disease
a. Decreasing or undetectable ß-hCG 
levels
1 1 1 1 3 3
b. Persistently elevated ß-hCG levels 
or malignant disease§ 
1 1 1 1 4 4
Cervical ectropion 1 1 1 1 1 1
Cervical intraepithelial neoplasia 2 1 2 2 2 1
Cervical cancer (awaiting treatment) Initiation Continuation Initiation Continuation
2 1 2 2 4 2 4 2
Breast disease
a. Undiagnosed mass 2† 2† 2† 2† 2 1
b. Benign breast disease 1 1 1 1 1 1
c.  Family history of cancer 1 1 1 1 1 1
d. Breast cancer§
 i. Current 4 4 4 4 4 1
 ii. Past and no evidence of 
current disease for 5 yrs
3 3 3 3 3 1
Endometrial hyperplasia 1 1 1 1 1 1
Endometrial cancer§ Initiation Continuation Initiation Continuation
1 1 1 1 4 2 4 2
Ovarian cancer§ 1 1 1 1 1 1
Uterine fibroids 1 1 1 1 2 2
Anatomical abnormalities
a. Distorted uterine cavity (any con-
genital or acquired uterine abnor-
mality distorting the uterine cavity 
in a manner that is incompatible 
with IUD insertion)
4 4
b. Other abnormalities (including 
cervical stenosis or cervical lacera-
tions) not distorting the uterine 
cavity or interfering with IUD 
insertion
2 2
Pelvic inflammatory disease (PID)
a. Past PID (assuming no current risk 
factors of STIs) Initiation Continuation Initiation Continuation
 i. With subsequent pregnancy 1 1 1 1 1 1 1 1
 ii. Without subsequent pregnancy 1 1 1 1 2 2 2 2
b. Current PID 1 1 1 1 4 2† 4 2†
80 Early Release May 28, 2010
TABLE. (Continued) Summary of classifications for hormonal contraceptive methods and intrauterine devices*
Condition COC/P/R POP DMPA Implants LNG-IUD Cu-IUD
STIs Initiation Continuation Initiation Continuation
a. Current purulent cervicitis or chla-
mydial infection or gonorrhea
1 1 1 1 4 2† 4 2†
b. Other STIs (excluding HIV and 
hepatitis)
1 1 1 1 2 2 2 2
c. Vaginitis (including Trichomonas 
vaginalis and bacterial vaginosis)
1 1 1 1 2 2 2 2
d. Increased risk for STIs 1 1 1 1 2/3† 2 2/3† 2
HIV/AIDS
Initiation Continuation Initiation Continuation
High risk for HIV 1 1 1 1 2 2 2 2
HIV infection§ 1 1 1 1 2 2 2 2
AIDS§ 1† 1† 1† 1† 3 2† 3 2†
Clinically well on ARV therapy If on treatment, see Drug Interactions section below 2 2 2 2
Other Infections
Schistosomiasis
a. Uncomplicated 1 1 1 1 1 1
b. Fibrosis of the liver (if severe, 
see Cirrhosis)§
1 1 1 1 1 1
Tuberculosis§ Initiation Continuation Initiation Continuation
a. Nonpelvic 1† 1† 1† 1† 1 1 1 1
b. Pelvic 1† 1† 1† 1† 4 3 4 3
If on treatment, see Drug Interactions section below
Malaria 1 1 1 1 1 1
Endocrine Conditions
Diabetes
a. History of gestational disease 1 1 1 1 1 1
b. Nonvascular disease
 i. Noninsulin-dependent 2 2 2 2 2 1
 ii. Insulin-dependent§ 2 2 2 2 2 1
c. Nephropathy/retinopathy/
neuropathy§
3/4† 2 3 2 2 1
d. Other vascular disease or diabetes 
of >20 yrs’ duration§
3/4† 2 3 2 2 1
Thyroid disorders
a. Simple goiter 1 1 1 1 1 1
b. Hyperthyroid 1 1 1 1 1 1
c. Hypothyroid 1 1 1 1 1 1
Gastrointestinal Conditions
Inflammatory bowel disease (IBD)
(ulcerative colitis, Crohn disease)
2/3† 2 2 1 1 1
Gallbladder disease
a. Symptomatic
 i. Treated by cholecystectomy 2 2 2 2 2 1
 ii. Medically treated 3 2 2 2 2 1
 iii. Current 3 2 2 2 2 1
b. Asymptomatic 2 2 2 2 2 1
History of cholestasis
a. Pregnancy-related 2 1 1 1 1 1
b. Past COC-related 3 2 2 2 2 1
Viral hepatitis Initiation Continuation
a. Acute or flare 3/4† 2 1 1 1 1 1
b. Carrier 1 1 1 1 1 1 1
c. Chronic 1 1 1 1 1 1 1
Cirrhosis
a. Mild (compensated) 1 1 1 1 1 1
b. Severe§ (decompensated) 4 3 3 3 3 1
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TABLE. (Continued) Summary of classifications for hormonal contraceptive methods and intrauterine devices*
Condition COC/P/R POP DMPA Implants LNG-IUD Cu-IUD
Liver tumors
a. Benign
 i. Focal nodular hyperplasia 2 2 2 2 2 1
 ii. Hepatocellular adenoma§ 4 3 3 3 3 1
b. Malignant§ (hepatoma) 4 3 3 3 3 1
Anemias
Thalassemia 1 1 1 1 1 2
Sickle cell disease§ 2 1 1 1 1 2
Iron-deficiency anemia 1 1 1 1 1 2
Solid Organ Transplantation
Solid organ transplantation§ Initiation Continuation Initiation Continuation
a. Complicated: graft failure (acute or 
chronic), rejection, cardiac allograft 
vasculopathy
4 2 2 2 3 2 3 2
b. Uncomplicated 2† 2 2 2 2 2
Drug Interactions
Antiretroviral therapy (see appendix M) Initiation Continuation Initiation Continuation
a.  Nucleoside reverse transcriptase 
inhibitors (NRTIs)
1† 1 1 1 2/3† 2† 2/3† 2†
b.  Non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs)
2† 2† 1 2† 2/3† 2† 2/3† 2†
c.  Ritonavir-boosted protease 
inhibitors
3† 3† 1 2† 2/3† 2† 2/3† 2†
Anticonvulsant therapy
a. Certain anticonvulsants (phe-
nytoin, carbamazepine, barbi-
turates, primidone, topiramate, 
oxcarbazepine)
3† 3† 1 2† 1 1
b. Lamotrigine 3† 1 1 1 1 1
Antimicrobial therapy
a.  Broad-spectrum antibiotics 1 1 1 1 1 1
b. Antifungals 1 1 1 1 1 1
c. Antiparasitics 1 1 1 1 1 1
d. Rifampicin or rifabutin therapy 3† 3† 1 2† 1 1
* Abbreviations: COC = combined oral contraceptive; P = combined hormonal contraceptive patch; R = combined hormonal vaginal ring; POP = progestin-only pill; DMPA = depot 
medroxyprogesterone acetate; IUD = intrauterine device; LNG-IUD = levonorgestrel-releasing IUD; Cu-IUD = copper IUD; BMI = body mass index; DVT = deep venous thrombo-
sis; PE = pulmonary embolism; hCG, = human chorionic gonadotropin; PID = pelvic inflammatory disease; STI = sexually transmitted infection; HIV = human immunodeficiency 
virus; AIDS = acquired immunodeficiency syndrome; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase.
† Consult the appendix for this contraceptive method for a clarification to this classification. 
§ Condition that exposes a woman to increased risk as a result of unintended pregnancy.
Reference
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Appendix M
 Summary of Evidence Regarding Potential Drug Interactions between 
Hormonal Contraception and Antiretroviral therapies
Limited data from small, mostly unpublished studies sug-
gest that some antiretroviral (ARV) therapies might alter the 
pharmacokinetics of combined oral contraceptives (COCs). 
Few studies have measured clinical outcomes. However, con-
traceptive steroid levels in the blood decrease substantially with 
ritonavir-boosted protease inhibitors. Such decreases have the 
potential to compromise contraceptive effectiveness. Some of 
the interactions between contraceptives and ARVs also have 
led to increased ARV toxicity. For smaller effects that occur 
with non-nucleoside reverse transcriptase inhibitors, clinical 
significance is unknown, especially because studies have not 
examined steady-state levels of contraceptive hormones. No 
clinically significant interactions have been reported between 
contraceptive hormones and nucleoside reverse transcriptase 
inhibitors.
Tables 1 and 2 summarize the evidence available about drug 
interactions between ARV therapies and hormonal contra-
ceptives. For up-to-date, detailed information about human 
immunodeficiency virus (HIV) drug interactions, the following 
resources might be helpful: 
Guidelines for the Use of Antiretroviral Agents in HIV-•	
1-Infected Adults and Adolescents from the DHHS 
Panel on Antiretroviral Guidelines for Adults and 
Adolescents. Available at http://aidsinfo.nih.gov/content-
files/AdultandAdolescentGL.pdf. 
HIV Drug Interactions website, University of Liverpool, •	
UK. Available at www.hiv-druginteractions.org.
TABLE 1. Drug interactions between COCs and ARV drugs*
ARV Contraceptive effects† ARV effects†
Nucleoside reverse transcriptase inhibitors (NRTIs)
Tenofovir disaproxil fumarate EE ↔, NGM ↔ (1) Tenofovir ↔ (1)
Zidovudine No data Zidovudine ↔ (2) 
No change in viral load or CD4+ (2)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz EE ↑ (3), EE ↔ (4), NGM ↓ (4), LNG ↓ (4) 
Pregnancy rate 2.6/100 woman-years in 1 
study in which up to 80% used hormonal 
contraceptives (35% used COC) (5)
Efavirenz ↔ (3,4)
Etravirine EE ↔, NET ↔ (6) Etravirine ↑ (6)
Concurrent administration, generally safe and well tolerated 
(6)
Nevirapine EE ↔, NET ↔ (7) Nevirapine ↔ (7)
Protease inhibitors and ritonavir-boosted protease inhibitors
Atazanavir/ritonavir EE ↑, NET ↑ (8) No data
Darunavir/ritonavir EE ↓, NET	↔ (9) Darunavir ↔ (9)
Fos-amprenavir/ritonavir EE ↓ (10,11), NET ↓ (11) Amprenavir ↔, ritonavir ↑, Elevated liver transaminases (10)
Indinavir§ EE ↔, NET	↔ (12) No data
Lopinavir/ritonavir EE ↓, NET ↔ (13) No data
Nelfinavir EE ↓, NET	↔ (14) No data
Saquinavir§ No data Saquinavir ↔ (15,16)
Tipranavir/ritonavir EE↓ (17) ↑ Skin and musculoskeletal adverse events; possible drug 
hypersensitivity reaction (17)
* Abbreviations: COC = combined oral contraceptive; ARV = antiretroviral; EE = ethinyl estradiol; NGM = norgestimate; NNRTI = non-nucleoside reverse 
transcriptase inhibitor; LNG = levonorgestrel; NET = norethindrone.
† ↔, no change or change ≤30%; ↑, increase >30%; ↓, decrease >30%.
§ Saquinavir and indinavir are commonly given boosted by ritonavir, but there are no data on contraceptive interactions with the boosted regimens.
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TABLE 2. Drug interactions between DMPA and ARV drugs*
ARV Contraceptive effects† ARV effects†
Nucleoside reverse transcriptase inhibitors (NRTIs)
Zidovudine No data Zidovudine ↔ (2) 
No change in viral load
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz MPA ↔ (18,19)  
No ovulations during 3 cycles(18,19) 
 
Pregnancy rate 2.6/100 woman-years in 1 study where 
up to 80% used hormonal contraceptives (65% used 
POIs) (5)
Efavirenz ↔ (18) 
No change in viral load or CD4+, no grade 3- or 4-related adverse 
events§ (20)
Nevirapine MPA ↔ (18) 
No ovulations during 3 cycles(18)
Nevirapine ↑ (18) 
No change in viral load or CD4+, no grade 3- or 4-related adverse 
events§ (20)
Protease inhibitors and ritonavir-boosted protease inhibitors 
Nelfinavir MPA	↔ (18) Nelfinavir ↔ (18) 
No change in viral load or CD4+, no grade 3- or 4-related adverse 
events§ (20)
* Abbreviations: DMPA = depot medroxyprogesterone acetate; ARV = antiretroviral; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside 
reverse transcriptase; MPA = medroxyprogesterone acetate; POI = progestin-only injectables.
† ↔, no change or change ≤30%; ↑, increase > 30%.
§ The trial applied the standardized National Institutes of Health Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events, 2004 
(http://rcc.tech-res.com/Document/safetyandpharmacovigilance/DAIDS_AE_GradingTable_Clarification_August2009_Final.pdf). Grade 3 events are clas-
sified as severe. Severe events are defined as symptoms that limit activity or might require some assistance; require medical intervention or therapy; and 
might require hospitalization. Grade 4 events are classified as life threatening. Life-threatening events include symptoms that result in extreme limitation 
of activity and require substantial assistance; require substantial medical intervention and therapy; and probably require hospitalization or hospice.
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Abbreviations and Acronyms
A  accept
AIDS  acquired immunodeficiency syndrome
ARV  antiretroviral
BMD  bone mineral density
BMI  body mass index
C  caution
CDC    Centers for Disease Control and Prevention
CHC  combined hormonal contraceptive
CI  coitus interruptus
COC   combined oral contraceptive
Cu-IUD copper intrauterine device
D  delayed
DMPA  depot medroxyprogesterone acetate
DVT  deep venous thrombosis
ECP  emergency contraceptive pills
EE  ethinyl estradiol
E-IUD  emergency intrauterine device
ETG  etonogestrel
FAB  fertility awareness–based methods
hCG  human chorionic gonadotropin
HDL  high-density lipoprotein
HIV  human immunodeficiency virus
HPV  human papillomavirus
IBD  inflammatory bowel disease
IUS  intrauterine system
IUD  intrauterine device
LNG  levonorgestrel
LNG-IUD levonorgestrel-releasing intrauterine device
MEC  Medical Eligibility Criteria
NET-EN norethisterone enantate
NGM  norgestimate
NNRTI  non-nucleoside reverse transcriptase inhibitor
NRTI  nucleoside reverse transcriptase inhibitor
P  combined hormonal contraceptive patch
PE  pulmonary embolism
PID  pelvic inflammatory disease
POC  progestin-only contraceptive
POI  progestin-only injectable
POP  progestin-only pill
R  combined hormonal vaginal ring
SLE  systemic lupus erythematosus
STI  sexually transmitted infection
VTE  venous thromboembolism
WHO   World Health Organization
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